Source: Basiswettenbestand
URL: data/BWBV0001829/2019-01-01_0/xml/BWBV0001829_2019-01-01_0.xml

Document:
BWBV0001829_2018-01-01_0
  Internationaal Verdrag tegen doping in de sport 200619415-09-200617-11-20062007518-01-200701-02-2007
  Internationaal Verdrag tegen doping in de sport 200619415-09-200617-11-20062007518-01-200701-02-2007
  
  
  
    International Convention Against Doping in Sport
  
  
    
      Preamble
    
    The General Conference of the United Nations Educational, Scientific and Cultural Organization, hereinafter referred to as UNESCO, meeting in Paris from 3 to 21 October 2005, at its 33rd session,
    Considering that the aim of UNESCO is to contribute to peace and security by promoting collaboration among nations through education, science and culture,
    Referring to existing international instruments relating to human rights,
    Aware of resolution 58/5 adopted by the General Assembly of the United Nations on 3 November 2003, concerning sport as a means to promote education, health, development and peace, notably its paragraph 7,
    Conscious that sport should play an important role in the protection of health, in moral, cultural and physical education and in promoting international understanding and peace,
    Noting the need to encourage and coordinate international cooperation towards the elimination of doping in sport, 
    Concerned by the use of doping by athletes in sport and the consequences thereof for their health, the principle of fair play, the elimination of cheating and the future of sport,
    Mindful that doping puts at risk the ethical principles and educational values embodied in the International Charter of Physical Education and Sport of UNESCO and in the Olympic Charter,
    Recalling that the Anti-Doping Convention and its Additional Protocol adopted within the framework of the Council of Europe are the public international law tools, which are at the origin of national anti-doping policies and of intergovernmental cooperation,
    Recalling the Recommendations on doping adopted by the second, third and fourth International Conferences of Ministers and Senior Officials responsible for Physical Education and Sport organized by UNESCO at Moscow (1988), Punta del Este (1999) and Athens (2004) and 32 C/Resolution 9 adopted by the General Conference of UNESCO at its 32nd session (2003),
    Bearing in mind the World Anti-Doping Code adopted by the World Anti-Doping Agency at the World Conference on Doping in Sport, Copenhagen, 5 March 2003 and the Copenhagen Declaration on Anti-Doping in Sport,
    Mindful also of the influence that elite athletes have on youth,
    Aware of the ongoing need to conduct and promote research with the objectives of improving detection of doping and better understanding of the factors affecting use in order for prevention strategies to be most effective,
    Aware also of the importance of ongoing education of athletes, athlete support personnel and the community at large in preventing doping,
    Mindful of the need to build the capacity of States Parties to implement anti-doping programmes,
    Aware that public authorities and the organizations responsible for sport have complementary responsibilities to prevent and combat doping in sport, notably to ensure the proper conduct, on the basis of the principle of fair play, of sports events and to protect the health of those that take part in them,
    Recognizing that these authorities and organizations must work together for these purposes ensuring the highest degree of independence and transparency at all appropriate levels,
    Determined to take further and stronger cooperative action aimed at the elimination of doping in sport,
    Recognizing that the elimination of doping in sport is dependent in part upon progressive harmonization of anti-doping standards and practices in sport and cooperation at the national and global levels, 
    Adopts this Convention on this nineteenth day of October 2005.
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    PART
     I
    SCOPE
  
  
    Article
    1
    Purpose of the Convention
  
  The purpose of this Convention, within the framework of the strategy and programme of activities of UNESCO in the area of physical education and sport, is to promote the prevention of and the fight against doping in sport, with a view to its elimination.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    2
    Definitions
  
  These definitions are to be understood within the context of the World Anti-Doping Code. However, in case of conflict the provisions of the Convention will prevail.
  For the purposes of this Convention:
  
    
      1.
      “Accredited doping control laboratories” means laboratories accredited by the World Anti-Doping Agency.
    
    
      2.
      “Anti-doping organization” means an entity that is responsible for adopting rules for initiating, implementing or enforcing any part of the doping control process. This includes, for example, the International Olympic Committee, the International Paralympic Committee, other major event organizations that conduct testing at their events, the World Anti-Doping Agency, international federations, and national anti-doping organizations.
    
    
      3.
      “Anti-doping rule violation” in sport means one or more of the following:
      
        
          a)
          the presence of a prohibited substance or its metabolites or markers in an athlete’s bodily specimen;
        
        
          b)
          use or attempted use of a prohibited substance or a prohibited method;
        
        
          c)
          refusing, or failing without compelling justification, to submit to sample collection after notification as authorized in applicable anti-doping rules or otherwise evading sample collection;
        
        
          d)
          violation of applicable requirements regarding athlete availability for out-of-competition testing including failure to provide required whereabouts information and missed tests which are declared based on reasonable rules;
        
        
          e)
          tampering, or attempting to tamper, with any part of doping control; 
        
        
          f)
          possession of prohibited substances or methods;
        
        
          g)
          trafficking in any prohibited substance or prohibited method;
        
        
          h)
          administration or attempted administration of a prohibited substance or prohibited method to any athlete, or assisting, encouraging, aiding, abetting, covering up or any other type of complicity involving an anti-doping rule violation or any attempted violation.
        
      
    
    
      4.
      “Athlete” means, for the purposes of doping control, any person who participates in sport at the international or national level as defined by each national anti-doping organization and accepted by States Parties and any additional person who participates in a sport or event at a lower level accepted by States Parties. For the purposes of education and training programmes, “athlete” means any person who participates in sport under the authority of a sports organization.
    
    
      5.
      “Athlete support personnel” means any coach, trainer, manager, agent, team staff, official, medical or paramedical personnel working with or treating athletes participating in or preparing for sports competition.
    
    
      6.
      “Code” means the World Anti-Doping Code adopted by the World Anti-Doping Agency on 5 March 2003 at Copenhagen which is attached as Appendix 1 to this Convention.
    
    
      7.
      “Competition” means a single race, match, game or singular athletic contest.
    
    
      8.
      “Doping control” means the process including test distribution planning, sample collection and handling, laboratory analysis, results management, hearings and appeals.
    
    
      9.
      “Doping in sport” means the occurrence of an anti-doping rule violation
    
    
      10.
      “Duly authorized doping control teams” means doping control teams operating under the authority of international or national anti-doping organizations.
    
    
      11.
      “In-competition” testing means, for purposes of differentiating between in-competition and out-of-competition testing, unless provided otherwise in the rules of an international federation or other relevant anti-doping organization, a test where an athlete is selected for testing in connection with a specific competition.
    
    
      12.
      “International Standard for Laboratories” means the standard which is attached as Appendix 2 to this Convention
    
    
      13.
      “International Standard for Testing” means the standard which is attached as Appendix 3 to this Convention.
    
    
      14.
      “No advance notice” means a doping control which takes place with no advance warning to the athlete and where the athlete is continuously chaperoned from the moment of notification through sample provision.
    
    
      15.
      “Olympic Movement” means all those who agree to be guided by the Olympic Charter and who recognize the authority of the International Olympic Committee, namely: the international federations of sports on the programme of the Olympic Games; the National Olympic Committees, the Organizing Committees of the Olympic Games, athletes, judges and referees, associations and clubs, as well as all the organizations and institutions recognized by the International Olympic Committee.
    
    
      16.
      “Out-of-competition” doping control means any doping control which is not conducted in competition.
    
    
      17.
      “Prohibited List” means the list which appears in Annex I to this Convention identifying the prohibited substances and prohibited methods.
    
    
      18.
      “Prohibited method” means any method so described on the Prohibited List, which appears in Annex I to this Convention.
    
    
      19.
      “Prohibited substance” means any substance so described on the Prohibited List, which appears in Annex I to this Convention.
    
    
      20.
      “Sports organization” means any organization that serves as the ruling body for an event for one or several sports.
    
    
      21.
      “Standards for Granting Therapeutic Use Exemptions” means those standards that appear in Annex II to this Convention.
    
    
      22.
      “Testing” means the parts of the doping control process involving test distribution planning, sample collection, sample handling, and sample transport to the laboratory.
    
    
      23.
      “Therapeutic use exemption” means an exemption granted in accordance with Standards for Granting Therapeutic Use Exemptions.
    
    
      24.
      “Use” means the application, ingestion, injection or consumption by any means whatsoever of any prohibited substance or prohibited method.
    
    
      25.
      “World Anti-Doping Agency (WADA)” means the foundation so named established under Swiss law on 10 November 1999.
    
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    3
    Means to achieve the purpose of the Convention
  
  In order to achieve the purpose of the Convention, States Parties undertake to:
  
    
      a.
      adopt appropriate measures at the national and international levels which are consistent with the principles of the Code;
    
    
      b.
      encourage all forms of international cooperation aimed at protecting athletes and ethics in sport, and at sharing the results of research; 
    
    
      c.
      foster international cooperation between States Parties and leading organizations in the fight against doping in sport, in particular with the World Anti-Doping Agency.
    
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    4
    Relationship of the Convention to the Code
  
  
    1
    In order to coordinate the implementation, at the national and international levels, of the fight against doping in sport, States Parties commit themselves to the principles of the Code, as the basis for the measures provided for in Article 5 of this Convention. Nothing in this Convention prevents States Parties from adopting additional measures complementary to the Code.
  
  
    2
    The Code and the most current version of Appendices 2 and 3 are reproduced for information purposes, and are not an integral part of this Convention. The Appendices as such do not create any binding obligations under international law for States Parties.
  
  
    3
    The Annexes are an integral part of this Convention.
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    5
    Measures to achieve the objectives of the Convention
  
  In abiding by the obligations contained in this Convention, each State Party undertakes to adopt appropriate measures. Such measures may include legislation, regulation, policies or administrative practices.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    6
    Relationship to other international instruments
  
  This Convention shall not alter the rights and obligations of States Parties which arise from other agreements previously concluded and consistent with the object and purpose of this Convention. This does not affect the enjoyment by other States Parties of their rights or the performance of their obligations under this Convention.
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    PART 
    II
    ANTI-DOPING ACTIVITIES AT THE NATIONAL LEVEL
  
  
    Article
    7
    Domestic coordination
  
  States Parties shall ensure the application of the present Convention, notably through domestic coordination. To meet their obligations under this Convention, States Parties may rely on anti-doping organizations as well as sports authorities and organizations.
200619415-09-200617-11-200615829-09-20168815-06-20152007518-01-200701-02-2007
  
    Article
    8
    Restricting the availability and use in sport of prohibited substances and methods
  
  
    1
    States Parties shall, where appropriate, adopt measures to restrict the availability of prohibited substances and methods in order to restrict their use in sport by athletes, unless the use is based upon a therapeutic use exemption. These include measures against trafficking to athletes, and to this end, measures to control production, movement, importation, distribution and sale.
  
  
    2
    States Parties shall adopt, or encourage, where appropriate, the relevant entities within their jurisdictions to adopt measures to prevent and to restrict the use and possession of prohibited substances and methods by athletes in sport unless the use is based upon a therapeutic use exemption.
  
  
    3
    No measures taken pursuant to this Convention will impede the availability for legitimate purposes, of substances and methods otherwise prohibited or controlled in sport.
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    9
    Measures against athlete support personnel
  
  States Parties shall themselves take measures or encourage sports organizations and anti-doping organizations to adopt measures, including sanctions or penalties, aimed at athlete support personnel who commit an anti-doping rule violation or other offence connected with doping in sport.
200619415-09-200617-11-20068815-06-201515829-09-20162007518-01-200701-02-2007Abusievelijk is een opdracht tot correctie geformuleerd die niet
    geheel juist is.
  
    Article
    10
    Nutritional supplements
  
  States Parties, where appropriate, shall encourage producers and distributors of nutritional supplements to establish best practices in the marketing and distribution of nutritional supplements, including information regarding their analytic composition and quality assurance.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    11
    Financial measures
  
  States Parties shall, where appropriate:
  
    
      a)
      provide funding within their respective budgets to support a national testing programme across all sports or assist sports organizations and anti-doping organizations in financing doping controls either by direct subsidies or grants, or by recognizing the costs of such controls when determining the overall subsidies or grants to be awarded to those organizations;
    
    
      b)
      take steps to withhold sport-related financial support to individual athletes or athlete support personnel who have been suspended following an anti-doping rule violation, during the period of their suspension;
    
    
      c)
      withhold some or all financial or other sport-related support from any sports organization or anti-doping organization not in compliance with the Code or applicable anti-doping rules adopted pursuant to the Code.
    
  
200619415-09-200617-11-20068815-06-201515829-09-20162007518-01-200701-02-2007
  
    Article
    12
    Measures to facilitate doping control
  
  States Parties shall, where appropriate:
  
    
      a)
      encourage and facilitate the implementation by sports organizations and anti-doping organizations within their jurisdiction of doping controls in a manner consistent with the Code including no-advance notice, out-of-competition and in-competition testing;
    
    
      b)
      encourage and facilitate the negotiation by sports organizations and anti-doping organizations of agreements permitting their members to be tested by duly authorized doping control teams from other countries;
    
    
      c)
      undertake to assist the sports organizations and anti-doping organizations within their jurisdiction in gaining access to an accredited doping control laboratory for the purposes of doping control analysis.
    
  
200619415-09-200617-11-200615829-09-20168815-06-20152007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    PART 
    III
    INTERNATIONAL COOPERATION
  
  
    Article
    13
    Cooperation between anti-doping organizations and sports organizations
  
  States Parties shall encourage cooperation between anti-doping organizations, public authorities, and sports organizations within their jurisdiction and those within the jurisdiction of other States Parties in order to achieve, at the international level, the purpose of this Convention.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    14
    Supporting the mission of the World Anti-Doping Agency
  
  States Parties undertake to support the important mission of the World Anti-Doping Agency in the international fight against doping. 
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    15
    Equal funding of the World Anti-Doping Agency
  
  States Parties support the principle of equal funding of the World Anti-Doping Agency’s approved annual core budget by public authorities and the Olympic Movement.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    16
    International cooperation in doping control
  
  Recognizing that the fight against doping in sport can only be effective when athletes can be tested with no advance notice and samples can be transported in a timely manner to laboratories for analysis, States Parties shall, where appropriate and in accordance with domestic law and procedures:
  
    
      a)
      facilitate the task of the World Anti-Doping Agency and anti-doping organizations operating in compliance with the Code, subject to relevant host countries’ regulations, of conducting in- or out-of-competition doping controls on their athletes, whether on their territory or elsewhere;
    
    
      b)
      facilitate the timely movement of duly authorized doping control teams across borders when conducting doping control activities;
    
    
      c)
      cooperate to expedite the timely shipping or carrying across borders of samples in such a way as to maintain their security and integrity;
    
    
      d)
      assist in the international coordination of doping controls by various anti-doping organizations, and cooperate to this end with the World Anti-Doping Agency;
    
    
      e)
      promote cooperation between doping control laboratories within their jurisdiction and those within the jurisdiction of other States Parties. In particular, States Parties with accredited doping control laboratories should encourage laboratories within their jurisdiction to assist other States Parties in enabling them to acquire the experience, skills and techniques necessary to establish their own laboratories should they wish to do so;
    
    
      f)
      encourage and support reciprocal testing arrangements between designated anti-doping organizations, in conformity with the Code;
    
    
      g)
      mutually recognize the doping control procedures and test results management, including the sport sanctions thereof, of any anti-doping organization that are consistent with the Code.
    
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    17
    Voluntary Fund
  
  
    1
    A “Fund for the Elimination of Doping in Sport”, hereinafter referred to as “the Voluntary Fund”, is hereby established. The Voluntary Fund shall consist of funds-in-trust established in accordance with the Financial Regulations of UNESCO. All contributions by States Parties and other actors shall be voluntary.
  
  
    2
    The resources of the Voluntary Fund shall consist of:
    
      
        a)
        contributions made by States Parties;
      
      
        b)
        contributions, gifts or bequests which may be made by:
        
          
            (i)
            other States;
          
          
            (ii)
            organizations and programmes of the United Nations system, particularly the United Nations Development Programme, as well as other international organizations; 
          
          
            (iii)
            public or private bodies or individuals;
          
        
      
      
        c)
        any interest due on the resources of the Voluntary Fund;
      
      
        d)
        funds raised through collections, and receipts from events organized for the benefit of the Voluntary Fund;
      
      
        e)
        any other resources authorized by the Voluntary Fund’s regulations, to be drawn up by the Conference of Parties.
      
    
  
  
    3
    Contributions into the Voluntary Fund by States Parties shall not be considered to be a replacement for States Parties’ commitment to pay their share of the World Anti-Doping Agency’s annual budget.
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007Abusievelijk geeft het Tractatenblad een opdracht tot een
    correctie van het tweede lid die niet geheel juist is.
  
    Article
    18
    Use and governance of the Voluntary Fund
  
  Resources in the Voluntary Fund shall be allocated by the Conference of Parties for the financing of activities approved by it, notably to assist States Parties in developing and implementing anti-doping programmes, in accordance with the provisions of this Convention, taking into consideration the goals of the World Anti-Doping Agency, and may serve to cover functioning costs of this Convention. No political, economic or other conditions may be attached to contributions made to the Voluntary Fund.
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    PART 
    IV
    EDUCATION AND TRAINING
  
  
    Article
    19
    General education and training principles
  
  
    1
    States Parties shall undertake, within their means, to support, devise or implement education and training programmes on anti-doping. For the sporting community in general, these programmes should aim to provide updated and accurate information on:
    
      
        a)
        the harm of doping to the ethical values of sport; 
      
      
        b)
        the health consequences of doping.
      
    
  
  
    2
    For athletes and athlete support personnel, in particular in their initial training, education and training programmes should, in addition to the above, aim to provide updated and accurate information on:
    
      
        a)
        doping control procedures;
      
      
        b)
        athletes’ rights and responsibilities in regard to anti-doping, including information about the Code and the anti-doping policies of the relevant sports and anti-doping organizations. Such information shall include the consequences of committing an anti-doping rule violation;
      
      
        c)
        the list of prohibited substances and methods and therapeutic use exemptions;
      
      
        d)
        nutritional supplements.
      
    
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    20
    Professional codes of conduct
  
  States Parties shall encourage relevant competent professional associations and institutions to develop and implement appropriate codes of conduct, good practice and ethics related to anti-doping in sport that are consistent with the Code.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    21
    Involvement of athletes and athlete support personnel
  
  States Parties shall promote and, within their means, support active participation by athletes and athlete support personnel in all facets of the anti-doping work of sports and other relevant organizations and encourage sports organizations within their jurisdiction to do likewise.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    22
    Sports organizations and ongoing education and training on anti-doping
  
  States Parties shall encourage sports organizations and anti-doping organizations to implement ongoing education and training programmes for all athletes and athlete support personnel on the subjects identified in Article 19.
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    23
    Cooperation in education and training
  
  States Parties shall cooperate mutually and with the relevant organizations to share, where appropriate, information, expertise and experience on effective anti-doping programmes. 
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    PART 
    V
    RESEARCH
  
  
    Article
    24
    Promotion of research in anti-doping
  
  States Parties undertake, within their means, to encourage and promote anti-doping research in cooperation with sports and other relevant organizations on:
  
    
      a)
      prevention, detection methods, behavioural and social aspects, and the health consequences of doping;
    
    
      b)
      ways and means of devising scientifically-based physiological and psychological training programmes respectful of the integrity of the person;
    
    
      c)
      the use of all emerging substances and methods resulting from scientific developments.
    
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    25
    Nature of anti-doping research
  
  When promoting anti-doping research, as set out in Article 24, States Parties shall ensure that such research will:
  
    
      a)
      comply with internationally recognized ethical practices;
    
    
      b)
      avoid the administration to athletes of prohibited substances and methods;
    
    
      c)
      be undertaken only with adequate precautions in place to prevent the results of anti-doping research being misused and applied for doping.
    
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    26
    Sharing the results of anti-doping research
  
  Subject to compliance with applicable national and international law, States Parties shall, where appropriate, share the results of available anti-doping research with other States Parties and the World Anti-Doping Agency.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    27
    Sport science research
  
  States Parties shall encourage:
  
    
      a)
      members of the scientific and medical communities to carry out sport science research in accordance with the principles of the Code; 
    
    
      b)
      sports organizations and athlete support personnel within their jurisdiction to implement sport science research that is consistent with the principles of the Code.
    
  
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    PART 
    VI
    MONITORING OF THE CONVENTION
  
  
    Article
    28
    Conference of Parties
  
  
    1
    A Conference of Parties is hereby established. The Conference of Parties shall be the sovereign body of this Convention.
  
  
    2
    The Conference of Parties shall meet in ordinary session in principle every two years. It may meet in extraordinary session if it so decides or at the request of at least one third of the States Parties.
  
  
    3
    Each State Party shall have one vote at the Conference of Parties.
  
  
    4
    The Conference of Parties shall adopt its own Rules of Procedure.
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    29
    Advisory organization and observers to the Conference of Parties
  
  The World Anti-Doping Agency shall be invited as an advisory organization to the Conference of Parties. The International Olympic Committee, the International Paralympic Committee, the Council of Europe, and the Intergovernmental Committee for Physical Education and Sport (CIGEPS) shall be invited as observers. The Conference of Parties may decide to invite other relevant organizations as observers.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    30
    Functions of the Conference of Parties
  
  
    1
    Besides those set forth in other provisions of this Convention, the functions of the Conference of Parties shall be to:
    
      
        a)
        promote the purpose of this Convention;
      
      
        b)
        discuss the relationship with the World Anti-Doping Agency and study the mechanisms of funding of the Agency’s annual core budget. States non-Parties may be invited to the discussion;
      
      
        c)
        adopt a plan for the use of the resources of the Voluntary Fund, in accordance with Article 18;
      
      
        d)
        examine the reports submitted by States Parties in accordance with Article 31;
      
      
        e)
        examine, on an ongoing basis, the monitoring of compliance with this Convention in response to the development of anti-doping systems, in accordance with Article 31. Any monitoring mechanism or measure that goes beyond Article 31 shall be funded through the Voluntary Fund established under Article 17;
      
      
        f)
        examine draft amendments to this Convention for adoption;
      
      
        g)
        examine for approval, in accordance with Article 34 of the Convention, modifications to the Prohibited List and to the Standards for Granting Therapeutic Use Exemptions adopted by the World Anti-Doping Agency;
      
      
        h)
        define and implement cooperation between States Parties and the World Anti-Doping Agency within the framework of this Convention;
      
      
        i)
        request a report from the World Anti-Doping Agency on the implementation of the Code to each of its sessions for examination.
      
    
  
  
    2
    The Conference of Parties, in fulfilling its functions, may cooperate with other intergovernmental bodies.
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    31
    National reports to the Conference of Parties
  
  States Parties shall forward every two years to the Conference of Parties through the Secretariat, in one of the official languages of UNESCO, all relevant information concerning measures taken by them for the purpose of complying with the provisions of this Convention.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    32
    Secretariat of the Conference of Parties
  
  
    1
    The Secretariat of the Conference of Parties shall be provided by the Director-General of UNESCO.
  
  
    2
    At the request of the Conference of Parties the Director-General of UNESCO shall use to the fullest extent possible the services of the World Anti-Doping Agency on terms agreed upon by the Conference of Parties.
  
  
    3
    Functioning costs related to the Convention will be funded from the regular budget of UNESCO within existing resources at an appropriate level, the Voluntary Fund established under Article 17 or an appropriate combination thereof as determined every two years. The financing for the Secretariat from the regular budget shall be done on a strictly minimal basis, it being understood that voluntary funding should also be provided to support the Convention.
  
  
    4
    The Secretariat shall prepare the documentation of the Conference of Parties, as well as the draft agenda of its meetings, and shall ensure the implementation of its decisions. 
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    33
    Amendments
  
  
    1
    Each State Party may, by written communication addressed to the Director-General of UNESCO, propose amendments to this Convention. The Director-General shall circulate such communication to all States Parties. If, within six months from the date of the circulation of the communication, at least one half of the States Parties give their consent, the Director-General shall present such proposals to the following session of the Conference of Parties.
  
  
    2
    Amendments shall be adopted by the Conference of Parties with a two-thirds majority of States Parties present and voting.
  
  
    3
    Once adopted, amendments to this Convention shall be submitted for ratification, acceptance, approval or accession to States Parties.
  
  
    4
    With respect to the States Parties that have ratified, accepted, approved or acceded to them, amendments to this Convention shall enter into force three months after the deposit of the instruments referred to in paragraph 3 of this Article by two thirds of the States Parties. Thereafter, for each State Party that ratifies, accepts, approves or accedes to an amendment, the said amendment shall enter into force three months after the date of deposit by that State Party of its instrument of ratification, acceptance, approval or accession.
  
  
    5
    A State that becomes a Party to this Convention after the entry into force of amendments in conformity with paragraph 4 of this Article shall, failing an expression of different intention, be considered:
    
      
        a)
        a Party to this Convention as so amended;
      
      
        b)
        a Party to the unamended Convention in relation to any State Party not bound by the amendments.
      
    
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    34
    Specific amendment procedure for the Annexes to the Convention
  
  
    1
    If the World Anti-Doping Agency modifies the Prohibited List or the Standards for Granting Therapeutic Use Exemptions, it may, by written communication addressed to the Director-General of UNESCO, inform her/him of those changes. The Director-General shall notify such changes as proposed amendments to the relevant Annexes to this Convention to all States Parties expeditiously. Amendments to the Annexes shall be approved by the Conference of Parties either at one of its sessions or through a written consultation.
  
  
    2
    States Parties have 45 days from the Director-General’s notification within which to express their objection to the proposed amendment either in writing, in case of written consultation, to the Director-General or at a session of the Conference of Parties. Unless two thirds of the States Parties express their objection, the proposed amendment shall be deemed to be approved by the Conference of Parties.
  
  
    3
    Amendments approved by the Conference of Parties shall be notified to States Parties by the Director-General. They shall enter into force 45 days after that notification, except for any State Party that has previously notified the Director-General that it does not accept these amendments.
  
  
    4
    A State Party having notified the Director-General that it does not accept an amendment approved according to the preceding paragraphs remains bound by the Annexes as not amended.
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    PART 
    VII
    FINAL CLAUSES
  
  
    Article
    35
    Federal or non-unitary constitutional systems
  
  The following provisions shall apply to States Parties that have a federal or non-unitary constitutional system:
  
    
      a)
      With regard to the provisions of this Convention, the implementation of which comes under the legal jurisdiction of the federal or central legislative power, the obligations of the federal or central government shall be the same as for those States Parties which are not federal States;
    
    
      b)
      With regard to the provisions of this Convention, the implementation of which comes under the jurisdiction of individual constituent States, countries, provinces or cantons which are not obliged by the constitutional system of the federation to take legislative measures, the federal government shall inform the competent authorities of such States, countries, provinces or cantons of the said provisions, with its recommendation for their adoption.
    
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    36
    Ratification, acceptance, approval or accession
  
  This Convention shall be subject to ratification, acceptance, approval or accession by States Members of UNESCO in accordance with their respective constitutional procedures. The instruments of ratification, acceptance, approval or accession shall be deposited with the Director-General of UNESCO. 
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    37
    Entry into force
  
  
    1
    This Convention shall enter into force on the first day of the month following the expiration of a period of one month after the date of deposit of the thirtieth instrument of ratification, acceptance, approval or accession.
  
  
    2
    For any State that subsequently expresses its consent to be bound by it, the Convention shall enter into force on the first day of the month following the expiration of a period of one month after the date of deposit of its instrument of ratification, acceptance, approval or accession.
  
200619415-09-200617-11-200615829-09-20168815-06-20152007518-01-200701-02-2007Abusievelijk geeft het Tractatenblad een opdracht tot een
    correctie voor het tweede lid, derde regel, in plaats van tweede
    lid, vierde regel.
  
    Article
    38
    Territorial extension of the Convention
  
  
    1
    Any State may, when depositing its instrument of ratification, acceptance, approval or accession, specify the territory or territories for whose international relations it is responsible and to which this Convention shall apply.
  
  
    2
    Any State Party may, at any later date, by a declaration addressed to UNESCO, extend the application of this Convention to any other territory specified in the declaration. In respect of such territory the Convention shall enter into force on the first day of the month following the expiration of a period of one month after the date of receipt of such declaration by the depositary.
  
  
    3
    Any declaration made under the two preceding paragraphs may, in respect of any territory specified in such declaration, be withdrawn by a notification addressed to UNESCO. Such withdrawal shall become effective on the first day of the month following the expiration of a period of one month after the date of receipt of such a notification by the depositary.
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    39
    Denunciation
  
  Any State Party may denounce this Convention. The denunciation shall be notified by an instrument in writing, deposited with the Director-General of UNESCO. The denunciation shall take effect on the first day of the month following the expiration of a period of six months after the receipt of the instrument of denunciation. It shall in no way affect the financial obligations of the State Party concerned until the date on which the withdrawal takes effect.
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    40
    Depositary
  
  The Director-General of UNESCO shall be the Depositary of this Convention and amendments thereto. As the Depositary, the Director-General of UNESCO shall inform the States Parties to this Convention, as well as the other States Members of the Organization of:
  
    
      a)
      the deposit of any instrument of ratification, acceptance, approval or accession;
    
    
      b)
      the date of entry into force of this Convention in accordance with Article 37;
    
    
      c)
      any report prepared in pursuance of the provisions of Article 31;
    
    
      d)
      any amendment to the Convention or to the Annexes adopted in accordance with Articles 33 and 34 and the date on which the amendment comes into force;
    
    
      e)
      any declaration or notification made under the provisions of Article 38;
    
    
      f)
      any notification made under the provisions of Article 39 and the date on which the denunciation takes effect;
    
    
      g)
      any other act, notification or communication relating to this Convention.
    
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    41
    Registration
  
  In conformity with Article 102 of the Charter of the United Nations, this Convention shall be registered with the Secretariat of the United Nations at the request of the Director-General of UNESCO.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Article
    42
    Authoritative texts
  
  
    1
    This Convention including its Annexes has been drawn up in Arabic, Chinese, English, French, Russian and Spanish, the six texts being equally authoritative.
  
  
    2
    The Appendices to this Convention are provided in Arabic, Chinese, English, French, Russian and Spanish.
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Article
    43
    Reservations
  
  No reservations that are incompatible with the object and purpose of the present Convention shall be permitted. 
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    DONE in Paris, this nineteenth day of October 2005, in two authentic copies bearing the signature of the President of the General Conference of UNESCO at its 33rd session and of the Director-General of UNESCO, which shall be deposited in the archives of UNESCO.
  
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
  
    Annex
    I
    The 2019 prohibited list
    – World Anti-Doping Code
  
  
    
      
        Date of entry into force : 1 January 2019
      
    
    
      
        SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)
      
      In accordance with Article 4.2.2 of the World Anti-doping Code, all prohibited substances shall be considered as “specified substances” except substances in classes S1, S2, S.4.4, S.4.5, S6.A, and prohibited methods M1, M2 and M3.
      
        
          PROHIBITED SUBSTANCES
        
        
          
            S0
            NON-APPROVED SUBSTANCES
          
          Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.
        
        
          
            S1
            ANABOLIC AGENTS
          
          Anabolic agents are prohibited.
          
            
              1.
              
                ANABOLIC ANDROGENIC STEROIDS (AAS)
              
              
                
                  a.
                  
                    Exogenous2)For purposes of this section:“exogenous” refers to a substance which is not ordinarily produced by the body naturally. AAS, including:
                  
                    1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); Bolasterone; Calusterone; Clostebol; Danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol); Drostanolone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3’,4’:2,3]-5α-androstan-17β-ol); Gestrinone; Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one); Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); Mibolerone; Norboletone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]- 1’H-pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one);
                  and other substances with a similar chemical structure or similar biological effect(s).
                
                
                  b.
                  
                    Endogenous3“endogenous” refers to a substance which is ordinarily produced by the body naturally.
                    AAS and their Metabolites and isomers, when administered exogenously, including but not limited to:
                  
                    4-Androstenediol (androst-4-ene-3β,17β-diol); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); 5-Androstenedione (androst-5-ene-3,17-dione); 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 7-Keto-DHEA; 19-Norandrostenediol (estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α-androstan-3-one); Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Boldenone; Boldione (androsta-1,4-diene-3,17-dione); Epiandrosterone (3β-hydroxy-5α-androstan-17-one); Epi-dihydrotestosterone (17β-hydroxy-5β-androstan-3-one); Epitestosterone; Nandrolone (19-nortestosterone); Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); Testosterone.
                
              
            
            
              2.
              
                OTHER ANABOLIC AGENTS
              
              
                Including, but not limited to:
              
              Clenbuterol, selective androgen receptor modulators [SARMs, e.g. andarine, LGD-4033, enobosarm (ostarine) and RAD140], tibolone, zeranol and zilpaterol.
            
          
        
        
          
            S2
            PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS
          
          The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:
          
            
              1.
              Erythropoietins (EPO) and agents affecting erythropoiesis, including, but not limited to:
              
                
                  1.1
                  Erythropoietin-Receptor Agonists,e.g. Darbepoietin (dEPO); Erythropoietins (EPO); EPO based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO 530, peginesatide).
                
                
                  1.2
                  Hypoxia-inducible factor (HIF) activating agents, e.g. Argon; Cobalt; Daprodustat (GSK1278863); Molidustat (BAY 85-3934); Roxadustat (FG-4592); Vadadustat (AKB-6548); Xenon.
                
                
                  1.3
                  GATA inhibitors, e.g. K-11706.
                
                
                  1.4
                  TGF-beta (TGF-β) inhibitors, e.g. Luspatercept; Sotatercept.
                
                
                  1.5
                  Innate repair receptor agonists, e.g. Asialo EPO; Carbamylated EPO (CEPO).
                
              
            
            
              2.
              Peptide hormones and their Releasing Factors,
              
                
                  2.1
                  Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors in males, e.g. Buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin;
                
                
                  2.2
                  Corticotrophins and their releasing factors, e.g Corticorelin;
                
                
                  2.3
                  Growth Hormone (GH), its fragments and releasing factors, including, but not limited to:
                  Growth Hormone fragments, e.g. AOD-9604 and hGH 176-191; Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. lenomorelin (ghrelin) and its mimetics, e.g. anamorelin, ipamorelin, macimorelin and tabimorelin; GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin).
                
              
            
            
              3.
              Growth Factors and Growth Factor Modulators, including, but not limited to: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Thymosin-β4 and its derivatives e.g. TB-500; Vascular-Endothelial Growth Factor (VEGF).
            
          
          and other growth factors or growth factors modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilisation, regenerative capacity or fibre type switching.
        
        
          
            S3
            BETA-2 AGONISTS
          
          All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.
          Including, but not limited to:
          
            Fenoterol; Formoterol, Higenamine; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Salmeterol; Terbutaline; Tretoquinol (trimetoquinol); Tulobuterol; Vilanterol. 
          
            Except:
          
          
            
              •
              Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours starting from any dose;
            
            
              •
              Inhaled formoterol: maximum delivered dose 54 micrograms over 24 hours;
            
            
              •
              Inhaled salmeterol: maximum 200 micrograms over 24 hours.
            
          
          The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above.
        
        
          
            S4
            HORMONE AND METABOLIC MODULATORS
          
          The following hormone and metabolic modulators are prohibited:
          
            
              1.
              Aromatase inhibitors including, but not limited to:
              
                2-Androstenol (5α-androst-2-en-17-ol); 2-Androstenone (5α-androst-2-en-17-one); 3-Androstenol (5α-androst-3-en-17-ol); 3-Androstenone (5α-androst-3-en-17-one); 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone.
            
            
              2.
              Selective estrogen receptor modulators (SERMs) including, but not limited to:
              
                Raloxifene; Tamoxifen; Toremifene.
            
            
              3.
              Other anti-estrogenic substances including, but not limited to:
              
                Clomiphene; Cyclofenil; Fulvestrant.
            
            
              4.
              Agents preventing activin receptor IIB activation including, but not limited, to:
              
                Activin A-neutralising antibodies; Activin receptor IIB competitors such as:
              Decoy activin receptors (e.g. ACE-031); Anti-activin receptor IIB antibodies (e.g. bimagrumab); Myostatin inhibitors such as: Agents reducing or ablating myostatin expression; Myostatin-binding proteins (e.g. follistatin, myostatin propeptide); Myostatin-neuralising antibodies (e.g. domagrozumab, lndogrozumab, stamulumab).
            
            
              5.
              Metabolic modulators:
              
                
                  5.1
                  Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516);
                
                
                  5.2
                  Insulins and insulin-mimetics;
                
                
                  5.3
                  Meldonium;
                
                
                  5.4
                  Trimetazidine.
                
              
            
          
        
        
          
            S5
            DIURETICS AND MASKING AGENTS
          
          The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).
          
            Including, but not limited to:
          
          
            
              •
              Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol.
            
            
              •
              Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.
            
          
          
            Except:
          
          
            
              •
              Drospirenone; pamabrom; and ophtalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide).
            
            
              •
              Local administration of felypressin in dental anaesthesia.
            
          
          The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent.
        
      
      
        
          PROHIBITED METHODS
        
        
          
            M1
            MANIPULATION OF BLOOD AND BLOOD COMPONENTS
          
          
            The following are prohibited:
          
          
            
              1.
              The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.
            
            
              2.
              Artificially enhancing the uptake, transport or delivery of oxygen.
              Including, but not limited to: 
              Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.
            
            
              3.
              Any form of intravascular manipulation of the blood or blood components by physical or chemical means.
            
          
        
        
          
            M2
            CHEMICAL AND PHYSICAL MANIPULATION
          
          
            The following are prohibited:
          
          
            
              1.
              
                Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control.
              Including, but not limited to:
              Urine substitution and/or adulteration, e.g. proteases.
            
            
              2.
              Intravenous infusions and/or injections of more than a total of 100 mL per 12 hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.
            
          
        
        
          
            M3
            GENE AND CELL DOPING
          
          
            The following, with the potential to enhance sport performance, are prohibited:
          
          
            
              1.
              The use of polymers of nucleic acids or nucleic acid analogues.
            
            
              2.
              The use of gene editing agents designed to alter genome sequences and/or the transcriptional, post-transcriptional or epigenetic regulation of gene expression.
            
            
              3.
              The use of normal or genetically modified cells
            
          
        
      
    
    
      
        SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION 
      
      In addition to the classes S0 to S5 and M1 to M3 defined above, the following classes are prohibited in-competition:
      
        
          PROHIBITED SUBSTANCES
        
        
          
            S6
            STIMULANTS
          
          All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited.
          
            Stimulants include:
          
          
            
              a:
              
                Non-Specified Stimulants:
              
              
                Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine. Prolintane.
              A stimulant not expressly listed in this section is a Specified Substance.
            
            
              b:
              
                Specified Stimulants.
              
              Including, but not limited to:
              3-Methylhexan-2-amine (1,2-dimethylpentylamine); 4-Methylhexan-2-amine (methylhexaneamine); 4-Methylpentan-2-amine (1,3-dimethylbutylamine); 5-Methylhexan-2-amine (1,4-dimethylpentylamine); Benzfetamine; Cathine4)Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.; Cathinone and its analogues, e.g. mephedrone, methedrone, and α-pyrrolidinovalerophenone; Dimetamfetamine (dimethylamphetamine); Ephedrine5)Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.; Epinephrine6)Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine7)Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.; Methylphenidate; Nikethamide; Norfenefrine; Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine8)Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.; Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine), Tuaminoheptane;
            
          
          and other substances with a similar chemical structure or similar biological effect(s).
          
            Except:
          
          
            
              •
              Clonidine;
            
            
              •
              Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2019 Monitoring Program9)Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2019 Monitoring Program, and are not considered Prohibited Substances..
            
          
        
        
          
            S7
            NARCOTICS
          
          
            The following narcotics are prohibited:
          
          
            Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Nicomorphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine.
        
        
          
            S8
            CANNABINOIDS
          
          
            The following cannabinoids are prohibited:
          
          
            
              •
              Natural cannabinoids, e.g. cannabis, hashish and marijuana,
            
            
              •
              Synthetic cannabinoids e.g. Δ9-tetrahydrocannabinol (THC) and other cannabimimetics.
            
          
          
            Except:
          
          
            
              •
              Cannabidiol.
            
          
        
        
          
            S9
            GLUCOCORTICOIDS
          
          All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.
          
            Including but not limited to:
          
          
            Betamethasone; Budesonide; Cortisone; Deflazacort; Dexamethasone; Fluticasone; Hydrocortisone; Methylprednisolone; Prednisolone; Prednisone; Triamcinolone.
        
      
    
    
      
        SUBSTANCES PROHIBITED IN PARTICULAR SPORTS
      
      
        
          P1
          BETA-BLOCKERS
        
        Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated.
        
          
            •
            Archery (WA)10)Also prohibited Out-of-Competition
          
          
            •
            Automobile (FIA)
          
          
            •
            Billiards (all disciplines) (WCBS)
          
          
            •
            Darts (WDF)
          
          
            •
            Golf (IGF)
          
          
            •
            Shooting (ISSF, IPC)11)Also prohibited Out-of-Competition
          
          
            •
            Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air
          
          
            •
            Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea.
          
        
        
          Including but not limited to:
        
        
          Acebutolol; Alprenolol; Atenolol; Betaxolol; Bisoprolol; Bunolol; Carteolol; Carvedilol;
        Celiprolol; Esmolol; Labetalol; Metipranolol; Metoprolol; Nadolol; Oxprenolol; Pindolol; Propranolol; Sotalol; Timolol.
      
    
  
201821006-12-2018201821006-12-201801-01-2019
  
  
    Annex
    II
  
  
  
    PART
    ONE
    INTRODUCTION, CODE PROVISIONS AND DEFINITIONS
  
  
    1.0
    Introduction and Scope
  
  The International Standard for Therapeutic Use Exemptions is a mandatory International Standard developed as part of the World Anti-Doping Program.
  The purpose of the International Standard for Therapeutic Use Exemptions is to establish (a) the conditions that must be satisfied in order for a Therapeutic Use Exemption (or TUE) to be granted, permitting the presence of a Prohibited Substance in an Athlete’s Sample or the Athlete’s Use or Attempted Use, Possession and/or Administration or Attempted Administration of a Prohibited Substance or Prohibited Method for therapeutic reasons; (b) the responsibilities imposed on Anti-Doping Organizations in making and communicating TUE decisions; (c) the process for an Athlete to apply for a TUE; (d) the process for an Athlete to get a TUE granted by one Anti-Doping Organization recognized by another Anti-Doping Organization; (e) the process for WADA to review TUE decisions; and (f) the strict confidentiality provisions that apply to the TUE process.
  Terms used in this International Standard that are defined terms from the Code are written in italics. Terms that are defined in this International Standard are underlined.
20203906-04-202020203906-04-202001-01-201920203906-04-202020203906-04-202001-01-2019
  
    2.0
    Code Provisions
  
  The following articles in the 2015 Code are directly relevant to the International Standard for Therapeutic Use Exemptions:
20203906-04-202020203906-04-202001-01-2019
  
    Code Article
    4.4
    Therapeutic Use Exemptions (“TUEs”).
  
  
    4.4.1
    The presence of a Prohibited Substance or its Metabolites or Markers, and/or the Use or Attempted Use, Possession or Administration or Attempted Administration of a Prohibited Substance or Prohibited Method shall not be considered an anti-doping rule violation if it is consistent with the provisions of a TUE granted in accordance with the International Standard for Therapeutic Use Exemptions.
  
  
    4.4.2
    An Athlete who is not an International-Level Athlete should apply to his or her National Anti-Doping Organization for a TUE. If the National Anti- Doping Organization denies the application, the Athlete may appeal exclusively to the national-level appeal body described in Articles 13.2.2 and 13.2.3.
  
  
    4.4.3
    An Athlete who is an International-Level Athlete should apply to his or her International Federation.
    
      
        4.4.3.1
        Where the Athlete already has a TUE granted by his or her National Anti-Doping Organization for the substance or method in question, if that TUE meets the criteria set out in the International Standard for Therapeutic Use Exemptions, then the International Federation must recognize it. If the International Federation considers that the TUE does not meet those criteria and so refuses to recognize it, it must notify the Athlete and his or her National Anti- Doping Organization promptly, with reasons. The Athlete or the National Anti-Doping Organization shall have 21 days from such notification to refer the matter to WADA for review. If the matter is referred to WADA for review, the TUE granted by the National Anti- Doping Organization remains valid for national-level Competition and Out-of-Competition Testing (but is not valid for international-level Competition) pending WADA’s decision. If the matter is not referred to WADA for review, the TUE becomes invalid for any purpose when the 21-day review deadline expires.
      
      
        4.4.3.2
        If the Athlete does not already have a TUE granted by his or her National Anti-Doping Organization for the substance or method in question, the Athlete must apply directly to his or her International Federation for a TUE as soon as the need arises. If the International Federation (or the National Anti-Doping Organization, where it has agreed to consider the application on behalf of the International Federation) denies the Athlete’s application, it must notify the Athlete promptly, with reasons. If the International Federation grants the Athlete’s application, it must notify not only the Athlete but also his or her National Anti-Doping Organization, and if the National Anti-Doping Organization considers that the TUE does not meet the criteria set out in the International Standard for Therapeutic Use Exemptions, it has 21 days from such notification to refer the matter to WADA for review. If the National Anti-Doping Organization refers the matter to WADA for review, the TUE granted by the International Federation remains valid for international-level Competition and Out-of-Competition Testing (but is not valid for national-level Competition) pending WADA’s decision. If the National Anti-Doping Organization does not refer the matter to WADA for review, the TUE granted by the International Federation becomes valid for national-level Competition as well when the 21-day review deadline expires.
        
          [Comment to Article 4.4.3: If the International Federation refuses to recognize a TUE granted by a National Anti-Doping Organization only because medical records or other information are missing that are needed to demonstrate satisfaction with the criteria in the International Standard for Therapeutic Use Exemptions, the matter should not be referred to WADA. Instead, the file should be completed and re-submitted to the International Federation.
        
        
          If an International Federation chooses to test an Athlete who is not an International-Level Athlete, it must recognize a TUE granted to that Athlete by his or her National Anti-Doping Organization.]
        
      
    
  
  
    4.4.4
    A Major Event Organization may require Athletes to apply to it for a TUE if they wish to Use a Prohibited Substance or a Prohibited Method in connection with the Event. In that case:
    
      
        4.4.4.1
        The Major Event Organization must ensure a process is available for an Athlete to apply for a TUE if he or she does not already have one. If the TUE is granted, it is effective for its Event only.
      
      
        4.4.4.2
        Where the Athlete already has a TUE granted by his or her National Anti-Doping Organization or International Federation, if that TUE meets the criteria set out in the International Standard for Therapeutic Use Exemptions, the Major Event Organization must recognize it. If the Major Event Organization decides the TUE does not meet those criteria and so refuses to recognize it, it must notify the Athlete promptly, explaining its reasons.
      
      
        4.4.4.3
        A decision by a Major Event Organization not to recognize or not to grant a TUE may be appealed by the Athlete exclusively to an independent body established or appointed by the Major Event Organization for that purpose. If the Athlete does not appeal (or the appeal is unsuccessful), he or she may not Use the substance or method in question in connection with the Event, but any TUE granted by his or her National Anti-Doping Organization or International Federation for that substance or method remains valid outside of that Event.
        
          [Comment to Article 4.4.4.3: For example, the CAS Ad Hoc Division or a similar body may act as the independent appeal body for particular Events, or WADA may agree to perform that function. If neither CAS nor WADA are performing that function, WADA retains the right (but not the obligation) to review the TUE decisions made in connection with the Event at any time, in accordance with Article 4.4.6.]
        
      
    
  
  
    4.4.5
    If an Anti-Doping Organization chooses to collect a Sample from a Person who is not an International-Level or National-Level Athlete, and that Person is Using a Prohibited Substance or Prohibited Method for therapeutic reasons, the Anti-Doping Organization may permit him or her to apply for a retroactive TUE.
  
  
    4.4.6
    
      WADA must review an International Federation’s decision not to recognize a TUE granted by the National Anti-Doping Organization that is referred to it by the Athlete or the Athlete’s National Anti-Doping Organization. In addition, WADA must review an International Federation’s decision to grant a TUE that is referred to it by the Athlete’s National Anti- Doping Organization. WADA may review any other TUE decisions at any time, whether upon request by those affected or on its own initiative. If the TUE decision being reviewed meets the criteria set out in the International Standard for Therapeutic Use Exemptions, WADA will not interfere with it. If the TUE decision does not meet those criteria, WADA will reverse it.
    
      [Comment to Article 4.4.6: WADA shall be entitled to charge a fee to cover the costs of (a) any review it is required to conduct in accordance with Article 4.4.6; and (b) any review it chooses to conduct, where the decision being reviewed is reversed.]
    
  
  
    4.4.7
    Any TUE decision by an International Federation (or by a National Anti-Doping Organization where it has agreed to consider the application on behalf of an International Federation) that is not reviewed by WADA, or that is reviewed by WADA but is not reversed upon review, may be appealed by the Athlete and/or the Athlete’s National Anti-Doping Organization, exclusively to CAS.
    
      [Comment to Article 4.4.7: In such cases, the decision being appealed is the International Federation’s TUE decision, not WADA’s decision not to review the TUE decision or (having reviewed it) not to reverse the TUE decision. However, the time to appeal the TUE decision does not begin to run until the date that WADA communicates its decision. In any event, whether the decision has been reviewed by WADA or not, WADA shall be given notice of the appeal so that it may participate if it sees fit.]
    
  
  
    4.4.8
    A decision by WADA to reverse a TUE decision may be appealed by the Athlete, the National Anti-Doping Organization and/or the International Federation affected, exclusively to CAS.
  
  
    4.4.9
    A failure to take action within a reasonable time on a properly submitted application for grant/recognition of a TUE or for review of a TUE decision shall be considered a denial of the application.
  
20203906-04-202020203906-04-202001-01-2019
  
    Code Article
    13.4
    Appeals relating to TUEs
  
  
    TUE decisions may be appealed exclusively as provided in Article 4.4.
20203906-04-202020203906-04-202001-01-201920203906-04-202020203906-04-202001-01-2019
  
    3.0
    Definitions and Interpretation
  
  
    
      3.1
      Defined terms from the 2015 Code that are used in the International Standard for Therapeutic Use Exemptions:
      
        ADAMS:  The Anti-Doping Administration and Management System is a Web- based database management tool for data entry, storage, sharing, and reporting designed to assist stakeholders and WADA in their anti-doping operations in conjunction with data protection legislation.
      
         Administration: Providing, supplying, supervising, facilitating, or otherwise participating in the Use or Attempted Use by another Person of a Prohibited Substance or Prohibited Method. However, this definition shall not include the actions of bona fide medical personnel involving a Prohibited Substance or Prohibited Method used for genuine and legal therapeutic purposes or other acceptable justification and shall not include actions involving Prohibited Substances which are not prohibited in Out-of-Competition Testing unless the circumstances as a whole demonstrate that such Prohibited Substances are not intended for genuine and legal therapeutic purposes or are intended to enhance sport performance.
      
         Adverse Analytical Finding: A report from a WADA-accredited laboratory or other WADA-approved laboratory that, consistent with the International Standard for Laboratories and related Technical Documents, identifies in a Sample the presence of a Prohibited Substance or its Metabolites or Markers (including elevated quantities of endogenous substances) or evidence of the Use of a Prohibited Method.
      
         Anti-Doping Organization: A Signatory that is responsible for adopting rules for initiating, implementing or enforcing any part of the Doping Control process. This includes, for example, the International Olympic Committee, the International Paralympic Committee, other Major Event Organizations that conduct Testing at their Events, WADA, International Federations, and National Anti-Doping Organizations.
      
        Athlete: Any Person who competes in sport at the international level (as defined by each International Federation) or the national level (as defined by each National Anti-Doping Organization). An Anti-Doping Organization has discretion to apply anti-doping rules to an Athlete who is neither an International-Level Athlete nor a National-Level Athlete, and thus to bring them within the definition of “Athlete.” In relation to Athletes who are neither International-Level nor National-Level Athletes, an Anti-Doping Organization may elect to: conduct limited Testing or no Testing at all; analyze Samples for less than the full menu of Prohibited Substances; require limited or no whereabouts information; or not require advance TUEs. However, if an Article 2.1, 2.3 or 2.5 anti-doping rule violation is committed by any Athlete over whom an Anti-Doping Organization has authority who competes below the international or national level, then the Consequences set forth in the Code (except Article 14.3.2) must be applied. For purposes of Article 2.8 and Article 2.9 and for purposes of anti-doping information and education, any Person who participates in sport under the authority of any Signatory, government, or other sports organization accepting the Code is an Athlete.
      
        [Comment: This definition makes it clear that all International- and National-Level Athletes are subject to the anti-doping rules of the Code, with the precise definitions of international- and national-level sport to be set forth in the anti- doping rules of the International Federations and National Anti-Doping Organizations, respectively. The definition also allows each National Anti-Doping Organization, if it chooses to do so, to expand its anti-doping program beyond International- or National-Level Athletes to competitors at lower levels of Competition or to individuals who engage in fitness activities but do not compete at all. Thus, a National Anti-Doping Organization could, for example, elect to test recreational-level competitors but not require advance TUEs. But an anti-doping rule violation involving an Adverse Analytical Finding or Tampering, results in all of the Consequences provided for in the Code (with the exception of Article 14.3.2). The decision on whether Consequences apply to recreational-level Athletes who engage in fitness activities but never compete is left to the National Anti-Doping Organization. In the same manner, a Major Event Organization holding an Event only for masters-level competitors could elect to test the competitors but not analyze Samples for the full menu of Prohibited Substances. Competitors at all levels of Competition should receive the benefit of anti-doping information and education.]
      
      
        Code: The World Anti-Doping Code.
      
         Competition: A single race, match, game or singular sport contest. For example, a basketball game or the finals of the Olympic 100-meter race in athletics. For stage races and other sport contests where prizes are awarded on a daily or other interim basis the distinction between a Competition and an Event will be as provided in the rules of the applicable International Federation.
      
        Event: A series of individual Competitions conducted together under one ruling body (e.g., the Olympic Games, FINA World Championships, or Pan American Games).
      
        In-Competition: Unless provided otherwise in the rules of an International Federation or the ruling body of the Event in question, “In-Competition” means the period commencing twelve hours before a Competition in which the Athlete is scheduled to participate through the end of such Competition and the Sample collection process related to such Competition.
      
        [Comment: An International Federation or ruling body for an Event may establish an “In-Competition” period that is different than the Event Period.]
      
      
         International-Level Athlete: Athletes who compete in sport at the international level, as defined by each International Federation, consistent with the International Standard for Testing and Investigations.
      
        [Comment: Consistent with the International Standard for Testing and Investigations, the International Federation is free to determine the criteria it will use to classify Athletes as International-Level Athletes, e.g., by ranking, by participation in particular International Events, by type of license, etc. However, it must publish those criteria in clear and concise form, so that Athletes are able to ascertain quickly and easily when they will become classified as International- Level Athletes. For example, if the criteria include participation in certain International Events, then the International Federation must publish a list of those International Events.]
      
      
        Major Event Organizations: The continental associations of National Olympic Committees and other international multi-sport organizations that function as the ruling body for any continental, regional or other International Event.
      
        National Anti-Doping Organization: The entity(ies) designated by each country as possessing the primary authority and responsibility to adopt and implement anti-doping rules, direct the collection of Samples, the management of test results, and the conduct of hearings at the national level. If this designation has not been made by the competent public authority(ies), the entity shall be the country’s National Olympic Committee or its designee.
      
        National-Level Athlete: Athletes who compete in sport at the national level, as defined by each National Anti-Doping Organization, consistent with the International Standard for Testing and Investigations.
      
         Possession: The actual, physical Possession, or the constructive Possession (which shall be found only if the Person has exclusive control or intends to exercise control over the Prohibited Substance or Prohibited Method or the premises in which a Prohibited Substance or Prohibited Method exists); provided, however, that if the Person does not have exclusive control over the Prohibited Substance or Prohibited Method or the premises in which a Prohibited Substance or Prohibited Method exists, constructive Possession shall only be found if the Person knew about the presence of the Prohibited Substance or Prohibited Method and intended to exercise control over it. Provided, however, there shall be no anti- doping rule violation based solely on Possession if, prior to receiving notification of any kind that the Person has committed an anti-doping rule violation, the Person has taken concrete action demonstrating that the Person never intended to have Possession and has renounced Possession by explicitly declaring it to an Anti-Doping Organization. Notwithstanding anything to the contrary in this definition, the purchase (including by any electronic or other means) of a Prohibited Substance or Prohibited Method constitutes Possession by the Person who makes the purchase.
      
        [Comment: Under this definition, steroids found in an Athlete’s car would constitute a violation unless the Athlete establishes that someone else used the car; in that event, the Anti-Doping Organization must establish that, even though the Athlete did not have exclusive control over the car, the Athlete knew about the steroids and intended to have control over the steroids. Similarly, in the example of steroids found in a home medicine cabinet under the joint control of an Athlete and spouse, the Anti-Doping Organization must establish that the Athlete knew the steroids were in the cabinet and that the Athlete intended to exercise control over the steroids. The act of purchasing a Prohibited Substance alone constitutes Possession, even where, for example, the product does not arrive, is received by someone else, or is sent to a third party address.]
      
      
         Prohibited List: The List identifying the Prohibited Substances and Prohibited Methods.
      
        Prohibited Method: Any method so described on the Prohibited List.
      
        Prohibited Substance: Any substance, or class of substances, so described on the Prohibited List.
      
        Signatories: Those entities signing the Code and agreeing to comply with the
      
        Code, as provided in Article 23.
      
        Testing: The parts of the Doping Control process involving test distribution planning, Sample collection, Sample handling, and Sample transport to the laboratory.
      
        TUE: Therapeutic Use Exemption, as described in Article 4.4.
      
        Use: The utilization, application, ingestion, injection or consumption by any means whatsoever of any Prohibited Substance or Prohibited Method.
      
        WADA: The World Anti-Doping Agency.
    
    
      3.2
      Further defined term from the International Standard for the Protection of Privacy and Personal Information that is used in the International Standard for Therapeutic Use Exemptions:
      
        
          Personal Information
        : Information, including without limitation SensitivePersonal Information, relating to an identified or identifiable Participant or relating to other Persons whose information is Processed solely in the context of an Anti- Doping Organization’s Anti-Doping Activities.
      
        [3.2 Comment: It is understood that Personal Information includes, but is not limited to, information relating to an Athlete’s name, date of birth, contact details and sporting affiliations, whereabouts, designated therapeutic use exemptions (if any), anti-doping test results, and results management (including disciplinary hearings, appeals and sanctions). Personal Information also includes personal details and contact information relating to other Persons, such as medical professionals and other Persons working with, treating or assisting an Athlete in the context of Anti-Doping Activities. Such information remains Personal Information and is regulated by this Standard for the entire duration of its Processing, irrespective of whether the relevant individual remains involved in organized sport.]
      
    
    
      3.3
      Further defined terms specific to the International Standard for Therapeutic Use Exemptions:
      
        
          Therapeutic
        : Of or relating to the treatment of a medical condition by remedial agents or methods; or providing or assisting in a cure.
      
        
          Therapeutic Use Exemption Committee (or “TUEC”)
        : The panel established by an Anti-Doping Organization to consider applications for TUEs.
      
        
          WADA 
          TUEC
        : The panel established by WADA to review the TUE decisions of other Anti-Doping Organizations.
    
    
      3.4
      Interpretation:
      
        
          3.4.1
          Unless otherwise specified, references to articles are references to articles of the International Standard for Therapeutic Use Exemptions.
        
        
          3.4.2
          The comments annotating various provisions of the International Standard for Therapeutic Use Exemptions shall be used to interpret that International Standard.
        
        
          3.4.3
          The official text of the International Standard for Therapeutic Use Exemptions shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.
        
      
    
  
20203906-04-202020203906-04-202001-01-201920203906-04-202020203906-04-202001-01-201920203906-04-202020203906-04-202001-01-2019
  
    PART
    TWO
    STANDARDS AND PROCESS FOR GRANTING TUES
  
  
    4.0
    Obtaining a TUE 
  
  
    
      4.1
      An Athlete may be granted a TUE if (and only if) he/she can show, by a balance of probability, that each of the following conditions is met:
      
        
          a.
          The Prohibited Substance or Prohibited Method in question is needed to treat an acute or chronic medical condition, such that the Athlete would experience a significant impairment to health if the Prohibited Substance or Prohibited Method were to be withheld.
        
        
          b.
          The TherapeuticUse of the Prohibited Substance or Prohibited Method is highly unlikely to produce any additional enhancement of performance beyond what might be anticipated by a return to the Athlete’s normal state of health following the treatment of the acute or chronic medical condition.
        
        
          c.
          There is no reasonable Therapeutic alternative to the Use of the Prohibited Substance or Prohibited Method.
        
        
          d.
          The necessity for the Use of the Prohibited Substance or Prohibited Method is not a consequence, wholly or in part, of the prior Use (without a TUE) of a substance or method which was prohibited at the time of such Use.
          
            [Comment to 4.1: When a TUEC is deciding whether or not to recognize a TUE granted by another Anti-Doping Organization (see Article 7, below), and when WADA is reviewing a decision to grant (or not to grant) a TUE (see Article 8, below), the issue will be the same as it is for a TUEC that is considering an application for a TUE under article 6, below, i.e., has the Athlete demonstrated by a balance of probability that each of the conditions set out in article 4.1 is met?
          
          
            The WADA documents titled “Medical Information to Support the Decisions of TUECs”, posted on WADA’s website, should be used to assist in the application of these criteria in relation to particular medical conditions.]
          
        
      
    
    
      4.2
      Unless one of the exceptions set out in Article 4.3 applies, an Athlete who needs to Use a Prohibited Substance or Prohibited Method for Therapeutic reasons must obtain a TUE prior to Using or Possessing the substance or method in question.
    
    
      4.3
      An Athlete may only be granted retroactive approval for his/her Therapeutic
      
        Use of a Prohibited Substance or Prohibited Method (i.e., a retroactive TUE) if:
      
        
          a.
          Emergency treatment or treatment of an acute medical condition was necessary; or
        
        
          b.
          Due to other exceptional circumstances, there was insufficient time or opportunity for the Athlete to submit, or for the TUEC to consider, an application for the TUE prior to Sample collection; or
        
        
          c.
          The applicable rules required the Athlete (see comment to Article 5.1) or permitted the Athlete (see Code Article 4.4.5) to apply for a retroactive TUE; or
          
            [Comment to 4.3(c): Such Athletes are strongly advised to have a medical file prepared and ready to demonstrate their satisfaction of the TUE conditions set out at Article 4.1, in case an application for a retroactive TUE is necessary following Sample collection.]
          
        
        
          d.
          It is agreed, by WADA and by the Anti-Doping Organization to whom the application for a retroactive TUE is or would be made, that fairness requires the grant of a retroactive TUE.
          
            [Comment to 4.3(d): If WADA and/or the Anti-Doping Organization do not agree to the application of Article 4.3(d), that may not be challenged either as a defense to proceedings for an anti-doping rule violation, or by way of appeal, or otherwise.] 
          
        
      
    
  
20203906-04-202020203906-04-202001-01-201920203906-04-202020203906-04-202001-01-2019
  
    5.0
    TUE Responsibilities of Anti-Doping Organizations
  
  
    
      5.1
      
         Code Article 4.4 specifies (a) which Anti-Doping Organizations have authority to make TUE decisions; (b) how those TUE decisions should be recognized and respected by other Anti-Doping Organizations; and (c) when TUE decisions may be reviewed and/or appealed.
      
        [Comment to 5.1: See Annex 1 for a flow-chart summarizing the key provisions of Code Article 4.4.
      
      
        Code Article 4.4.2 specifies the authority of a National Anti-Doping Organization to make TUE decisions in respect of Athletes who are not International-Level Athletes. In case of dispute as to which National Anti-Doping Organization should deal with the TUE application of an Athlete who is not an International-Level Athlete, WADA will decide. WADA’s decision will be final and not subject to appeal.
      
      
        Where national policy requirements and imperatives lead a National Anti-Doping Organization to prioritize certain sports over others in its test distribution planning (as contemplated by Article 4.4.1 of the International Standard for Testing and Investigations), the National Anti-Doping Organization may decline to consider advance applications for TUEs from Athletes in some or all of the non-priority sports, but in that case it must permit any such Athlete from whom a Sample is subsequently collected to apply for a retroactive TUE. The National Anti-Doping Organization should publicize any such policy on its website for the benefit of affected Athletes.]
      
    
    
      5.2
      Each National Anti-Doping Organization, International Federation and Major Event Organization must establish a TUEC to consider whether applications for grant or recognition of TUEs meet the conditions set out in Article 4.1.
      
        [Comment to 5.2: While a Major Event Organization may choose to recognize pre- existing TUEs automatically, there must be a mechanism for Athletes participating in the Event to obtain a new TUE if the need arises. It is up to each Major Event Organization whether it sets up its own TUEC for this purpose, or rather whether it outsources the task by agreement to a third party (such as Sport Accord). The aim in each case should be to ensure that Athletes competing in such Events have the ability to obtain TUEs quickly and efficiently before they compete.]
      
      
        
          a.
          
            TUECs should include at least three physicians with experience in the care and treatment of Athletes and a sound knowledge of clinical, sports and exercise medicine. In cases involving Athletes with impairments, at least one TUEC member should possess general experience in the care and treatment of Athletes with impairments, or possess specific experience in relation to the Athlete’s particular impairment(s).
        
        
          b.
          In order to ensure a level of independence of decisions, at least a majority of the members of a TUEC should have no political responsibility in the Anti-Doping Organization that appoints them. All members of the TUEC must sign a conflict of interest and confidentiality declaration. (A template declaration is available on WADA’s website).
        
      
    
    
      5.3
      Each National Anti-Doping Organization, International Federation and Major Event Organization must establish a clear process for applying to its TUEC for a TUE that complies with the requirements of this International Standard. It must also publish details of that process by (at a minimum) posting the information in a conspicuous place on its website and sending the information to WADA. WADA may re-publish the same information on its own website.
    
    
      5.4
      Each National Anti-Doping Organization, International Federation and Major Event Organization must promptly report (in English or French) all decisions of its TUEC granting or denying TUEs, and all decisions to recognize or refusing to recognize other Anti-Doping Organizations’ TUE decisions, through ADAMS or any other system approved by WADA. In respect of TUEs granted, the information reported shall include (in English or French):
      
        
          a.
          not only the approved substance or method, but also the dosage(s), frequency and route of Administration permitted, the duration of the TUE, and any conditions imposed in connection with the TUE; and
        
        
          b.
          the TUE application form and the relevant clinical information (translated into English or French) establishing that the Article 4.1 conditions have been satisfied in respect of such TUE (for access only by WADA, the Athlete’s National Anti-Doping Organization and International Federation, and the Major Event Organization organizing an Event in which the Athlete wishes to compete).
          
            [Comment to 5.4: The process of recognition of TUEs is greatly facilitated by use of ADAMS.]
          
        
      
    
    
      5.5
      When a National Anti-Doping Organization grants a TUE to an Athlete, it must warn him/her in writing (a) that that TUE is valid at national level only, and (b) that if the Athlete becomes an International-Level Athlete or competes in an International Event, that TUE will not be valid for those purposes unless it is recognized by the relevant International Federation or Major Event Organization in accordance with Article 7.1. Thereafter, the National Anti-Doping Organization should help the Athlete to determine when he/she needs to submit the TUE to an International Federation or Major Event Organization for recognition, and should guide and support the Athlete through the recognition process.
    
    
      5.6
      Each International Federation and Major Event Organization must publish a notice (at a minimum, by posting it in a conspicuous place on its website and sending it to WADA) that sets out clearly (1) which Athletes coming under its jurisdiction are required to apply to it for a TUE, and when; (2) which TUE decisions of other Anti-Doping Organizations it will automatically recognize in lieu of such application, in accordance with Article 7.1(a); and (3) which TUE decisions of other Anti-Doping Organizations will have to be submitted to it for recognition, in accordance with Article 7.1(b). WADA may re-publish the notice on its own website.
    
    
      5.7
      Any TUE that an Athlete has obtained from a National Anti-Doping Organization shall not be valid if the Athlete becomes an International-Level Athlete or competes in an International Event unless and until the relevant International Federation recognizes that TUE in accordance with Article 7.0. Any TUE that an Athlete has obtained from an International Federation shall not be valid if the Athlete competes in an International Event organized by a Major Event Organization, unless and until the relevant Major Event Organization recognizes that TUE in accordance with Article 7.0. As a result, if the International Federation or Major Event Organization (as applicable) declines to recognize that TUE, then (subject to the Athlete’s rights of review and appeal) that TUE may not be relied upon to excuse the presence, Use, Possession or Administration of the Prohibited Substance or Prohibited Method mentioned in the TUE vis-à-vis that International Federation or Major Event Organization.
    
  
20203906-04-202020203906-04-202001-01-201920203906-04-202020203906-04-202001-01-2019
  
    6.0
    TUE Application Process
  
  
    
      6.1
      An Athlete who needs a TUE should apply as soon as possible. For substances prohibited In-Competition only, the Athlete should apply for a TUE at least 30 days before his/her next Competition, unless it is an emergency or exceptional situation. The Athlete should apply to his/her National Anti-Doping Organization, International Federation and/or a Major Event Organization (as applicable), using the TUE application form provided. Anti-Doping Organizations shall make the application form they want Athletes to use available for download from their websites. That form must be based on the “TUE Application Form” template available on WADA’s website. The template may be modified by Anti-Doping Organizations to include additional requests for information, but no sections or items may be removed.
    
    
      6.2
      The Athlete should submit the TUE application form to the relevant Anti-Doping Organization via ADAMS or as otherwise specified by the Anti-Doping Organization. The form must be accompanied by:
      
        
          a.
          a statement by an appropriately qualified physician, attesting to the need for the Athlete to Use the Prohibited Substance or Prohibited Method in question for Therapeutic reasons; and
        
        
          b.
          a comprehensive medical history, including documentation from the original diagnosing physician(s) (where possible) and the results of all examinations, laboratory investigations and imaging studies relevant to the application.
          
            [Comment to 6.2(b): The information submitted in relation to the diagnosis, treatment and duration of validity should be guided by the WADA documents titled “Medical Information to Support the Decisions of TUECs”.]
          
        
      
    
    
      6.3
      The Athlete should keep a complete copy of the TUE application form and of all materials and information submitted in support of that application.
    
    
      6.4
      A TUE application will only be considered by the TUEC following the receipt of a properly completed application form, accompanied by all relevant documents. Incomplete applications will be returned to the Athlete for completion and re-submission.
    
    
      6.5
      The TUEC may request from the Athlete or his/her physician any additional information, examinations or imaging studies, or other information that it deems necessary in order to consider the Athlete’s application; and/or it may seek the assistance of such other medical or scientific experts as it deems appropriate.
    
    
      6.6
      Any costs incurred by the Athlete in making the TUE application and in supplementing it as required by the TUEC are the responsibility of the Athlete.
    
    
      6.7
      The TUEC shall decide whether or not to grant the application as soon as possible, and usually (i.e., unless exceptional circumstances apply) within no more than 21 days of receipt of a complete application. Where a TUE application is made a reasonable time prior to an Event, the TUEC must use its best endeavors to issue its decision before the start of the Event.
    
    
      6.8
      The TUEC’s decision must be communicated in writing to the Athlete and must be made available to WADA and to other Anti-Doping Organizations via ADAMS or any other system approved by WADA, in accordance with Article 5.4.
      
        
          a.
          A decision to grant a TUE must specify the dosage(s), frequency, route and duration of Administration of the Prohibited Substance or Prohibited Method in question that the TUEC is permitting, reflecting the clinical circumstances, as well as any conditions imposed in connection with the TUE.
        
        
          b.
          A decision to deny a TUE application must include an explanation of the reason(s) for the denial.
        
      
    
    
      6.9
      Each TUE will have a specified duration, as decided by the TUEC, at the end of which the TUE will expire automatically. If the Athlete needs to continue to Use the Prohibited Substance or Prohibited Method after the expiry date, he/she must submit an application for a new TUE well in advance of that expiry date, so that there is sufficient time for a decision to be made on the application before the expiry date.
      
        [Comment to 6.9: The duration of validity should be guided by the WADA documents titled “Medical Information to Support the Decisions of TUECs”.]
      
    
    
      6.10
      A TUE will be withdrawn prior to expiry if the Athlete does not promptly comply with any requirements or conditions imposed by the Anti-Doping Organization granting the TUE. Alternatively a TUE may be reversed upon review by WADA or on appeal.
    
    
      6.11
      Where an Adverse Analytical Finding is issued shortly after a TUE for the Prohibited Substance in question has expired or has been withdrawn or reversed, the Anti-Doping Organization conducting the initial review of the Adverse Analytical Finding (Code Article 7.2) shall consider whether the finding is consistent with Use of the Prohibited Substance prior to the expiry, withdrawal or reversal of the TUE. If so, such Use (and any resulting presence of the Prohibited Substance in the Athlete’s Sample) is not an anti-doping rule violation.
    
    
      6.12
      In the event that, after his/her TUE is granted, the Athlete requires a materially different dosage, frequency, route or duration of Administration of the Prohibited Substance or Prohibited Method to that specified in the TUE, he/she must apply for a new TUE. If the presence, Use, Possession or Administration of the Prohibited Substance or Prohibited Method is not consistent with the terms of the TUE granted, the fact that the Athlete has the TUE will not prevent the finding of an anti-doping rule violation.
    
  
20203906-04-202020203906-04-202001-01-201920203906-04-202020203906-04-202001-01-2019
  
    7.0
    TUE Recognition Process
  
  
    
      7.1
      
        Code Article 4.4 requires Anti-Doping Organizations to recognize TUEs granted by other Anti-Doping Organizations that satisfy the Article 4.1 conditions. Therefore, if an Athlete who becomes subject to the TUE requirements of an International Federation or Major Event Organization already has a TUE, he/she should not submit an application for a new TUE to the International Federation or Major Event Organization. Instead:
      
        
          a.
          The International Federation or Major Event Organization may publish notice that it will automatically recognize TUE decisions made pursuant to Code Article 4.4 (or certain categories of such decisions, e.g., those made by specified Anti-Doping Organizations, or those relating to particular Prohibited Substances), provided that such TUE decisions have been reported in accordance with Article 5.4 and therefore are available for review by WADA. If the Athlete’s TUE falls into a category of TUEs that are automatically recognized in this way at the time the TUE is granted, he/she does not need to take any further action.
          
            [Comment to 7.1(a): To ease the burden on Athletes, automatic recognition of TUE decisions once they have been reported in accordance with Article 5.4 is strongly encouraged. If an International Federation or Major Event Organizer is not willing to grant automatic recognition of all such decisions, it should grant automatic recognition of as many such decisions as possible, e.g., by publishing a list of Anti-Doping Organizations whose TUE decisions it will recognize automatically, and/or a list of those Prohibited Substances for which it will automatically recognize TUEs. Publication should be in the same manner as is set out in Article 5.3, i.e., the notice should be posted on the International Federation’s website and sent to WADA and to National Anti-Doping Organizations.]
          
        
        
          b.
          In the absence of such automatic recognition, the Athlete shall submit a request for recognition of the TUE to the International Federation or Major Event Organization in question, either via ADAMS or as otherwise specified by that International Federation or Major Event Organization. The request should be accompanied by a copy of the TUE and the original TUE application form and supporting materials referenced at Articles 6.1 and 6.2 (unless the Anti-Doping Organization that granted the TUE has already made the TUE and supporting materials available via ADAMS or other system approved by WADA, in accordance with Article 5.4).
        
      
    
    
      7.2
      Incomplete requests for recognition of a TUE will be returned to the Athlete for completion and re-submission. In addition, the TUEC may request from the Athlete or his/her physician any additional information, examinations or imaging studies, or other information that it deems necessary in order to consider the Athlete’s request for recognition of the TUE; and/or it may seek the assistance of such other medical or scientific experts as it deems appropriate.
    
    
      7.3
      Any costs incurred by the Athlete in making the request for recognition of the TUE and in supplementing it as required by the TUEC are the responsibility of the Athlete.
    
    
      7.4
      The TUEC shall decide whether or not to recognize the TUE as soon as possible, and usually (i.e., unless exceptional circumstances apply) within no more than 21 days of receipt of a complete request for recognition. Where the request is made a reasonable time prior to an Event, the TUEC must use its best endeavors to issue its decision before the start of the Event.
    
    
      7.5
      The TUEC’s decision will be notified in writing to the Athlete and will be made available to WADA and to other Anti-Doping Organizations via ADAMS or any other system approved by WADA. A decision not to recognize a TUE must include an explanation of the reason(s) for the non-recognition.
    
  
20203906-04-202020203906-04-202001-01-201920203906-04-202020203906-04-202001-01-2019
  
    8.0
    Review of TUE Decisions by WADA 
  
  
    Code 
    Article 4.4.6 provides that WADA, in certain cases, must review TUE decisions of International Federations, and that it may review any other TUE decisions, in each case to determine compliance with the Article 4.1 conditions. WADA shall establish a WADA TUEC that meets the requirements of Article 5.2 to carry out such reviews.
  
    
      8.2
      Each request for review must be submitted to WADA in writing, and must be accompanied by payment of the application fee established by WADA, as well as copies of all of the information specified in Article 6.2 (or, in the case of review of a TUE denial, all of the information that the Athlete submitted in connection with the original TUE application). The request must be copied to the party whose decision would be the subject of the review, and to the Athlete (if he/she is not requesting the review).
    
    
      8.3
      Where the request is for review of a TUE decision that WADA is not obliged to review, WADA shall advise the Athlete as soon as practicable following receipt of the request whether or not it will refer the TUE decision to the  WADA  TUEC for review. If WADA decides not to refer the TUE decision, it will return the application fee to the Athlete. Any decision by WADA not to refer the TUE decision to the WADA TUEC is final and may not be appealed. However, the TUE decision may still be appealable, as set out in Code Article 4.4.7.
    
    
      8.4
      Where the request is for review of a TUE decision of an International Federation that WADA is obliged to review, WADA may nevertheless refer the decision back to the International Federation (a) for clarification (for example, if the reasons are not clearly set out in the decision); and/or (b) for re-consideration by the International Federation (for example, if the TUE was only denied because medical tests or other information required to demonstrate satisfaction of the Article 4.1 conditions were missing).
    
    
      8.5
      Where a request for review is referred to the WADA TUEC, the WADA TUEC may seek additional information from the Anti-Doping Organization and/or the Athlete, including further studies as described in Article 6.5, and/or it may obtain the assistance of other medical or scientific experts as it deems appropriate.
    
    
      8.6
      The WADA TUEC shall reverse any grant of a TUE that does not comply with the Article 4.1 conditions. Where the TUE reversed was a prospective TUE (rather than a retroactive TUE), such reversal shall take effect upon the date specified by WADA (which shall not be earlier than the date of WADA’s notification to the Athlete). The reversal shall not apply retroactively and the Athlete’s results prior to such notification shall not be Disqualified. Where the TUE reversed was a retroactive TUE, however, the reversal shall also be retroactive.
    
    
      8.7
      The WADA TUEC shall reverse any denial of a TUE where the TUE application met the Article 4.1 conditions, i.e., it shall grant the TUE.
    
    
      8.8
      Where the WADA TUEC reviews a decision of an International Federation that has been referred to it pursuant to Code Article 4.4.3 (i.e., a mandatory review), it may require whichever Anti-Doping Organization “loses” the review (i.e., the Anti-Doping Organization whose view it does not uphold) (a) to reimburse the application fee to the party that referred the decision to WADA (if applicable); and/or (b) to pay the costs incurred by WADA in respect of that review, to the extent they are not covered by the application fee.
    
    
      8.9
      Where the WADA TUEC reverses a TUE decision that WADA has decided in its discretion to review, WADA may require the Anti-Doping Organization that made the decision to pay the costs incurred by WADA in respect of that review.
    
    
      8.10
      
        WADA shall communicate the reasoned decision of the WADA TUEC promptly to the Athlete and to his/her National Anti-Doping Organization and International Federation (and, if applicable, the Major Event Organization).
    
  
20203906-04-202020203906-04-202001-01-201920203906-04-202020203906-04-202001-01-2019
  
    9.0
    Confidentiality of Information
  
  
    
      9.1
      The collection, storage, processing, disclosure and retention of Personal Information during the TUE process by Anti-Doping Organizations and WADA shall comply with the International Standard for the Protection of Privacy and Personal Information.
    
    
      9.2
      An Athlete applying for the grant of a TUE or for recognition of a TUE shall provide written consent:
      
        
          a.
          for the transmission of all information pertaining to the application to members of all TUECs with authority under this International Standard to review the file and, as required, other independent medical or scientific experts, and to all necessary staff (including WADA staff) involved in the management, review or appeal of TUE applications;
        
        
          b.
          for the Athlete’s physician(s) to release to the TUEC upon request any health information that the TUEC deems necessary in order to consider and determine the Athlete’s application; and
        
        
          c.
          for the decision on the application to be made available to all Anti- Doping Organizations with Testing authority and/or results management authority over the Athlete.
          
            [Comment to 9.2: Prior to collecting Personal Information or obtaining consent from an Athlete, the Anti-Doping Organization shall communicate to the Athlete the information set out in Article 7.1 of the International Standard for the Protection of Privacy and Personal Information.]
          
        
      
    
    
      9.3
      The TUE application shall be dealt with in accordance with the principles of strict medical confidentiality. The members of the TUEC, independent experts and the relevant staff of the Anti-Doping Organization shall conduct all of their activities relating to the process in strict confidence and shall sign appropriate confidentiality agreements. In particular they shall keep the following information confidential:
      
        
          a.
          All medical information and data provided by the Athlete and physician(s) involved in the Athlete’s care.
        
        
          b.
          All details of the application, including the name of the physician(s) involved in the process.
        
      
    
    
      9.4
      Should the Athlete wish to revoke the right of the TUEC to obtain any health information on his/her behalf, the Athlete shall notify his/her medical practitioner in writing of such revocation; provided that, as a result of that revocation, the Athlete’s application for a TUE or for recognition of an existing TUE will be deemed withdrawn without approval/recognition having been granted.
    
    
      9.5
      
        Anti-Doping Organizations shall only use information submitted by an Athlete in connection with a TUE application to evaluate the application and in the context of potential anti-doping rule violation investigations and proceedings.
    
  
20203906-04-202020203906-04-202001-01-201920203906-04-202020203906-04-202001-01-201920203906-04-202020203906-04-202001-01-2019
20203906-04-202020203906-04-202001-01-2019Voorheen Part two.
  
  
    ANNEX
    1:
    CODE ARTICLE 4.4 FLOW-CHART
  
  
  1. TUE procedure if Athlete is not an International-Level Athlete when need for TUE arises
  
    
  
  2. Athlete enters Event for which Major Event Organization (or “MEO”) has its own TUE requirements
  
    
  
  3. TUE Procedure if Athlete is an International-Level Athlete (and so subject to the International Federation’s TUE requirements) when need for TUE arises
  
    
  
20203906-04-202020203906-04-202001-01-2019
20203906-04-202020203906-04-202001-01-2019

  
  
  
    Internationaal Verdrag tegen doping in de sport
  
  
    
      Preambule
    
    De Algemene Conferentie van de Organisatie van de Verenigde Naties voor Onderwijs, Wetenschap en Cultuur, hierna aangeduid als UNESCO, bijeengekomen te Parijs van 3 tot en met 21 oktober 2005 tijdens haar 33e zitting, 
    Overwegend dat het doel van UNESCO is een bijdrage te leveren aan vrede en veiligheid door samenwerking tussen naties te bevorderen door middel van onderwijs, wetenschap en cultuur,
    Verwijzend naar bestaande internationale instrumenten inzake mensenrechten,
    Zich bewust van resolutie 58/5 aangenomen door de Algemene Vergadering van de Verenigde Naties op 3 november 2003, betreffende sport als middel om onderwijs, gezondheid, ontwikkeling en vrede te bevorderen, en met name paragraaf 7 daarvan,
    Zich er tevens van bewust dat sport een belangrijke rol dient te spelen bij de bescherming van de gezondheid, bij morele en culturele vorming en lichamelijke opvoeding en bij het bevorderen van wederzijds begrip en vrede in de wereld,
    Gelet op de noodzaak internationale samenwerking gericht op het uitbannen van doping in de sport te bevorderen en te coördineren,
    Bezorgd over het gebruik door sporters van dopingmiddelen in de sport en de gevolgen daarvan voor hun gezondheid, het beginsel van fair play, het uitbannen van bedrog en de toekomst van de sport,
    Indachtig het feit dat doping een bedreiging vormt voor de ethische beginselen en educatieve waarden vervat in het Internationale Handvest voor Lichamelijke Opvoeding en Sport van UNESCO en in het Olympisch Handvest,
    In herinnering roepend dat de Overeenkomst ter bestrijding van doping en het Aanvullend Protocol daarbij aangenomen in het kader van de Raad van Europa instrumenten van internationaal publiekrecht zijn, die ten grondslag liggen aan nationaal antidopingbeleid en aan intergouvernementele samenwerking,
    Herinnerend aan de Aanbevelingen inzake doping aangenomen tijdens de tweede, derde en vierde Internationale Conferentie van ministers en hoge ambtenaren verantwoordelijk voor lichamelijke opvoeding en sport, door UNESCO georganiseerd te Moskou (1988), Punta del Este (1999) en Athene (2004) en aan 32 C/Resolutie 9 aangenomen door de Algemene Conferentie van UNESCO tijdens haar 32e zitting (2003),
    Indachtig de Wereldantidopingcode aangenomen door het Mondiaal Antidopingagentschap tijdens de Wereldconferentie inzake doping in de sport, Kopenhagen, 5 maart 2003 en de Verklaring van Kopenhagen tegen het gebruik van doping in de sport,
    Tevens indachtig de invloed die topsporters hebben op de jeugd,
    Zich bewust van de permanente behoefte onderzoek uit te voeren en te bevorderen met als doel het verbeteren van de detectie van doping en een beter begrip van de factoren die van invloed zijn op het gebruik ervan teneinde tot zo doeltreffend mogelijke preventiestrategieën te komen, 
    Zich tevens bewust van het belang van voortdurende educatie van sporters, hun begeleiders en de maatschappij in het algemeen op het gebied van het voorkomen van doping,
    Indachtig de noodzaak de capaciteit van Staten die Partij zijn om antidopingprogramma’s te implementeren op te bouwen,
    Zich ervan bewust dat overheidsinstanties en sportorganisaties elkaar aanvullende verantwoordelijkheden hebben bij het voorkomen en bestrijden van doping in de sport, in het bijzonder het goede verloop, op basis van het beginsel van fair play, van sportevenementen, en bij het beschermen van de gezondheid van de deelnemers daaraan,
    Erkennend dat deze autoriteiten en organisaties daartoe dienen samen te werken en daarbij de hoogste mate van onafhankelijkheid en transparantie op alle van toepassing zijnde niveaus dienen te waarborgen,
    Vastbesloten nadere maatregelen te nemen, in hechtere samenwerking, gericht op de uitbanning van doping in de sport,
    Erkennend dat de uitbanning van doping in de sport ten dele afhankelijk is van de verdere harmonisatie van normen en praktijken op het gebied van de bestrijding van doping in de sport en samenwerking op nationaal en mondiaal niveau,
    Neemt dit Verdrag aan op 19 oktober 2005.
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    DEEL
     I
    REIKWIJDTE
  
  
    Artikel
    1
    Doelstelling van het Verdrag
  
  De doelstelling van dit Verdrag, in het kader van de strategie en het activiteitenprogramma van UNESCO op het gebied van lichamelijke opvoeding en sport, is het bevorderen van het voorkomen en bestrijden van doping in de sport, met het oog op de uitbanning ervan.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    2
    Begripsomschrijvingen
  
  Deze begripsomschrijvingen dienen begrepen te worden in de context van de Wereldantidopingcode. Indien de bepalingen daarvan in strijd zijn met die van het Verdrag, zijn de bepalingen van het Verdrag doorslaggevend.
  Voor de toepassing van dit Verdrag wordt verstaan onder:
  
    
      1.
      „Geaccrediteerde dopingcontrolelaboratoria’’ door het Mondiaal Antidopingagentschap geaccrediteerde laboratoria. 
    
    
      2.
      „Antidopingorganisatie’’ een orgaan dat verantwoordelijk is voor het aannemen van regels voor het in gang zetten, implementeren of handhaven van elk deel van het proces van dopingcontrole. Hieronder worden onder andere begrepen het Internationaal Olympisch Comité, het Internationaal Paralympisch Comité, andere organisatoren van grote evenementen die tijdens hun evenementen dopingcontroles uitvoeren, het Mondiaal Antidopingagentschap, internationale sportbonden en nationale antidopingorganisaties.
    
    
      3.
      „Schending van het antidopingreglement’’ in de sport een of meer van de onderstaande schendingen:
      
        
          a)
          de aanwezigheid van een verboden stof of een van haar metabolieten of markers in een lichaamsweefsel of lichaamsvloeistof van een sporter;
        
        
          b)
          gebruik of poging tot gebruik van een verboden stof of een verboden methode;
        
        
          c)
          weigering een monster af te staan na aankondiging zoals toegestaan door het toepasselijke antidopingreglement, of het nalaten hiervan zonder dwingende reden, of het anderszins vermijden van het afstaan van monsters;
        
        
          d)
          schending van de toepasselijke vereisten inzake de beschikbaarheid van sporters voor controles buiten wedstrijdverband met inbegrip van het verzuimen de vereiste informatie over de verblijfplaats te verstrekken en het missen van controles waarvan verklaard wordt dat zij zijn gebaseerd op redelijke regelgeving;
        
        
          e)
          manipuleren, of poging tot het manipuleren, van een onderdeel van een dopingcontrole;
        
        
          f)
          bezit van verboden stoffen of methoden;
        
        
          g)
          handel in een verboden stof of een verboden methode;
        
        
          h)
          toediening of poging tot toediening van een verboden stof of verboden methode aan een sporter, of hulp bij, aanmoediging van, medeplichtigheid aan, uitlokking van, verhulling van of enige andere vorm van medeplichtigheid aan een schending of poging tot schending van een antidopingreglement.
        
      
    
    
      4.
      „Sporter’’, ten behoeve van dopingcontrole, elke persoon die een sport beoefent op internationaal of nationaal niveau zoals omschreven door elke nationale antidopingorganisatie en door de Staten die Partij zijn aanvaard en elke andere persoon die een sport beoefent of aan een evenement deelneemt op een lager niveau dat door de Staten die Partij zijn is aanvaard. Ten behoeve van opleidings- en trainingsprogramma’s wordt onder „sporter’’ verstaan elke persoon die een sport beoefent die onder toezicht van een sportorganisatie staat.
    
    
      5.
      „Begeleiders van sporters’’ coaches, trainers, managers, zaakwaarnemers, teammedewerkers, officials, medisch of paramedisch personeel met wie een sporter die deelneemt aan of zich voorbereidt op deelname aan een sportwedstrijd samenwerkt of door wie deze wordt behandeld. 
    
    
      6.
      „Code’’ de Wereldantidopingcode aangenomen door het Mondiaal Antidopingagentschap op 5 maart 2003 te Kopenhagen, die als Aanhangsel 1 bij dit Verdrag is gevoegd.
    
    
      7.
      „Wedstrijd’’ een enkele race, match, partij of afzonderlijke sportieve krachtmeting.
    
    
      8.
      „Dopingcontrole’’ het volledige proces met inbegrip van het plannen van uit te voeren controles, verzamelen en hanteren van monsters, laboratoriumonderzoek, resultatenbeheer, hoorzittingen en beroepsprocedures.
    
    
      9.
      „Doping in de sport’’ het zich voordoen van een schending van het antidopingreglement.
    
    
      10.
      „Naar behoren gemachtigde dopingcontroleteams’’ dopingcontroleteams die onder de bevoegdheid van internationale of nationale antidopingorganisaties opereren.
    
    
      11.
      Controle „binnen wedstrijdverband’’ ten behoeve van het onderscheid tussen controles binnen wedstrijdverband en buiten wedstrijdverband, tenzij anderszins voorzien in het reglement van een internationale sportbond of andere relevante antidopingorganisatie, een controle waarbij een sporter voor controle wordt aangewezen in verband met een specifieke wedstrijd.
    
    
      12.
      „Internationale norm voor laboratoria’’ de norm die als Aanhangsel 2 bij dit Verdrag is gevoegd.
    
    
      13.
      „Internationale norm voor dopingcontroles’’ de norm die als Aanhangsel 3 bij dit Verdrag is gevoegd.
    
    
      14.
      „Onaangekondigd’’ een dopingcontrole die plaatsvindt zonder dat de sporter daarvan vooraf op de hoogte wordt gesteld en waarbij de sporter voordurend door een controleur wordt vergezeld vanaf het moment van de aankondiging tot en met de afname van het monster.
    
    
      15.
      „Onaangekondigd’’ een dopingcontrole die plaatsvindt zonder dat de sporter daarvan vooraf op de hoogte wordt gesteld en waarbij de sporter voordurend door een controleur wordt vergezeld vanaf het moment van de aankondiging tot en met de afname van het monster.
    
    
      16.
      Dopingcontrole „buiten wedstrijdverband’’ elke dopingcontrole die niet binnen wedstrijdverband plaatsvindt.
    
    
      17.
      „Lijst van verboden stoffen en methoden’’ de lijst vervat in Bijlage I bij dit Verdrag waarin de verboden stoffen en verboden methoden vermeld staan. 
    
    
      18.
      „Verboden methode’’ elke methode die als zodanig omschreven staat in de Lijst van verboden stoffen en methoden vervat in Bijlage I bij dit Verdrag.
    
    
      19.
      „Verboden stof’’ elke stof die als zodanig omschreven staat in de Lijst van verboden stoffen en methoden vervat in Bijlage I bij dit Verdrag.
    
    
      20.
      „Sportorganisatie’’ elke organisatie die de eindverantwoordelijkheid draagt voor een evenement met een of meer sporten.
    
    
      21.
      „Normen voor het verlenen van dispensatie voor therapeutisch gebruik’’ de normen vervat in Bijlage II bij dit Verdrag.
    
    
      22.
      „Controle’’ de onderdelen van het dopingcontroleproces inhoudende het plannen van de controles, het verzamelen en hanteren van monsters en het verzenden van monsters naar het laboratorium.
    
    
      23.
      „Dispensatie voor therapeutisch gebruik’’ een dispensatie verleend in overeenstemming met de normen voor het verlenen van dispensatie voor therapeutisch gebruik.
    
    
      24.
      „Gebruik’’ het aanbrengen, innemen, injecteren of op welke wijze dan ook consumeren van een verboden stof of verboden methode.
    
    
      25.
      „Mondiaal Antidopingagentschap (WADA)’’ de stichting die op 10 november 1999 onder deze naam werd opgericht naar Zwitsers recht.
    
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Artikel
    3
    Middelen om het doel van het Verdrag te verwezenlijken
  
  Ter verwezenlijking van het doel van het Verdrag verplichten de Staten die Partij zijn zich tot het:
  
    
      a.
      invoeren van passende maatregelen op nationaal en internationaal niveau die verenigbaar zijn met de beginselen van de Code;
    
    
      b.
      aanmoedigen van alle vormen van internationale samenwerking gericht op het beschermen van de sporters en de ethiek in de sport en op het delen van onderzoeksresultaten;
    
    
      c.
      bevorderen van internationale samenwerking tussen de Staten die Partij zijn en organisaties die een leidende rol hebben bij de bestrijding van doping in de sport, met name Mondiaal Antidopingagentschap.
    
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Artikel
    4
    Verhouding van het Verdrag tot de Code
  
  
    1
    Teneinde de implementatie van de bestrijding van doping in de sport op nationaal en internationaal niveau te coördineren verplichten de Staten die Partij zijn zich de beginselen van de Code te eerbiedigen, als basis voor de in artikel 5 van dit Verdrag vervatte maatregelen. Niets in dit Verdrag belet de Staten die Partij zijn andere maatregelen te nemen ter aanvulling van de Code.
  
  
    2
    De Code en de meest recente versie van de Aanhangsels 2 en 3 worden ter informatie verstrekt en vormen geen integrerend onderdeel van dit Verdrag. Uit de Bijlagen als zodanig vloeien voor de Staten die Partij zijn geen bindende verplichtingen voort uit hoofde van het internationaal recht.
  
  
    3
    De Bijlagen vormen een integrerend onderdeel van dit Verdrag.
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    5
    Maatregelen om de doelstellingen van dit Verdrag te verwezenlijken
  
  Door de in dit Verdrag vervatte verplichtingen te eerbiedigen, verplicht elke Staat die Partij is zich passende maatregelen in te voeren. Dergelijke maatregelen kunnen wetgeving, regulering, beleid of administratieve praktijken inhouden.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    6
    Verhouding tot andere internationale instrumenten
  
  Dit Verdrag heeft geen verandering tot gevolg van de rechten en verplichtingen van Staten die Partij zijn die voortvloeien uit eerder gesloten verdragen die verenigbaar zijn met het onderwerp en het doel van dit Verdrag. Dit doet geen afbreuk aan het genot van hun rechten door andere Staten die Partij zijn of de nakoming van hun verplichtingen uit hoofde van dit Verdrag.
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    DEEL
     II
    ANTIDOPINGACTIVITEITEN OP NATIONAAL NIVEAU
  
  
    Artikel
    7
    Coördinatie op nationaal niveau
  
  De Staten die Partij zijn, waarborgen de toepassing van dit Verdrag in het bijzonder door coördinatie op nationaal niveau. Teneinde hun verplichtingen ingevolge dit Verdrag na te komen, kunnen de Staten die Partij zijn zich verlaten op antidopingorganisaties alsmede op sportautoriteiten en -organisaties.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    8
    Beperking van de beschikbaarheid en het gebruik in de sport van verboden stoffen en methoden
  
  
    1
    De Staten die Partij zijn, nemen, wanneer van toepassing, maatregelen om de beschikbaarheid van verboden stoffen en methoden te beperken teneinde het gebruik ervan door sporters in de sport aan banden te leggen, tenzij er sprake is van dispensatie voor therapeutisch gebruik. Hieronder vallen maatregelen tegen de op sporters gerichte illegale handel in deze stoffen en methoden, en daaruit voortvloeiend, maatregelen om de productie, het verkeer, de invoer, distributie en verkoop ervan te controleren.
  
  
    2
    De Staten die Partij zijn, nemen maatregelen om het gebruik en het bezit van verboden stoffen en methoden door sporters in de sport te voorkomen en te beperken tenzij dit is toegestaan ingevolge een dispensatie voor therapeutisch gebruik, of moedigen, wanneer van toepassing, de relevante instanties onder hun rechtsmacht aan zulks te doen.
  
  
    3
    Geen van de uit hoofde van dit Verdrag genomen maatregelen beperkt de beschikbaarheid voor legitieme doeleinden van stoffen en methoden die in de sport verboden of aan banden gelegd zijn.
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    9
    Maatregelen tegen begeleiders van sporters
  
  De Staten die Partij zijn, nemen zelf maatregelen, met inbegrip van sancties of straffen, tegen begeleiders van sporters die het antidopingreglement schenden of een ander strafbaar feit met betrekking tot doping in de sport begaan, of moedigen sportorganisaties of antidopingorganisaties aan zulks te doen.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    10
    Voedingssupplementen
  
  De Staten die Partij zijn, moedigen, wanneer van toepassing, producenten en distributeurs van voedingssupplementen aan beste praktijken in te stellen op het gebied van marketing en distributie van voedingssupplementen, met inbegrip van informatie over hun analytische samenstelling en kwaliteitsborging.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    11
    Financiële maatregelen
  
  De Staten die Partij zijn,
  
    
      a)
      stellen, wanneer van toepassing, binnen hun respectieve begrotingen fondsen beschikbaar ter ondersteuning van een nationaal dopingcontroleprogramma in alle takken van sport of ondersteunen sportorganisaties en antidopingorganisaties bij het financieren van dopingcontroles, hetzij door hun daarvoor rechtstreeks subsidies of toelagen toe te kennen, hetzij door met de kosten van dergelijke controles rekening te houden bij het vaststellen van de subsidies of toelagen die aan deze organisaties worden toegekend; 
    
    
      b)
      nemen, wanneer van toepassing, stappen om de op de sport betrekking hebbende financiële ondersteuning in te trekken voor individuele sporters of begeleiders van sporters die geschorst zijn na een schending van een antidopingreglement, gedurende de periode waarin zij geschorst zijn;
    
    
      c)
      trekken, wanneer van toepassing, een gedeelte van of de volledige financiële steun of andere op de sport betrekking hebbende steun in voor elke sportorganisatie of antidopingorganisatie die zich niet aan de Code of het ingevolge de Code aangenomen antidopingreglement houdt.
    
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    12
    Maatregelen om dopingcontrole te vergemakkelijken
  
  De Staten die Partij zijn,
  
    
      a.
      bevorderen en vergemakkelijken, wanneer van toepassing, het uitvoeren van dopingcontroles door de sportorganisaties en antidopingorganisaties onder hun rechtsmacht op een wijze die verenigbaar is met de Code, met inbegrip van controles die onaangekondigd, buiten en binnen wedstrijdverband plaatsvinden;
    
    
      b.
      bevorderen en vergemakkelijken, wanneer van toepassing, onderhandelingen door sportorganisaties en antidopingorganisaties over overeenkomsten uit hoofde waarvan het wordt toegestaan hun leden te laten controleren door naar behoren bevoegde dopingcontroleteams uit andere landen;
    
    
      c.
      verplichten zich, wanneer van toepassing, de sportorganisaties en antidopingorganisaties onder hun rechtsmacht te helpen toegang te krijgen tot een geaccrediteerd dopingcontrolelaboratorium ten behoeve van de analyse van afgenomen monsters.
    
  
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    DEEL
    III
    INTERNATIONALE SAMENWERKING
  
  
    Artikel
    13
    Samenwerking tussen antidopingorganisaties en sportorganisaties
  
  De Staten die Partij zijn, bevorderen de samenwerking tussen antidopingorganisaties, overheidsinstanties en sportorganisaties onder hun rechtsmacht en die onder de rechtsmacht van andere Staten die Partij zijn, teneinde, op internationaal niveau, de doelstellingen van dit Verdrag te verwezenlijken.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    14
    Ondersteuning van de missie van het Mondiaal Antidopingagentschap
  
  De Staten die Partij zijn, verplichten zich de belangrijke missie van het Mondiaal Antidopingagentschap in de internationale dopingbestrijding te ondersteunen. 
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    15
    Evenredige financiering van het Mondiaal Antidopingagentschap
  
  De Staten die Partij zijn, ondersteunen het beginsel van evenredige financiering van de goedgekeurde jaarlijkse basisbegroting van het Mondiaal Antidopingagentschap door overheidsinstanties en de Olympische Beweging.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    16
    Internationale samenwerking bij dopingcontrole
  
  Erkennend dat de bestrijding van doping in de sport slechts doeltreffend kan zijn wanneer sporters onaangekondigd kunnen worden gecontroleerd en de monsters tijdig voor analyse naar laboratoria kunnen worden verzonden, nemen de Staten die Partij zijn, wanneer van toepassing en in overeenstemming met hun nationale wetgeving en procedures, de volgende maatregelen:
  
    
      a.
      vergemakkelijken van de taak van het Mondiaal Antidopingagentschap en antidopingorganisaties die overeenkomstig de Code werken, met inachtneming van de relevante regelgeving van de gastheerlanden, om binnen en buiten wedstrijdverband hun sporters op het gebruik van doping te controleren, hetzij op hun grondgebied, hetzij elders;
    
    
      b.
      vergemakkelijken van de tijdige grenspassage van naar behoren gemachtigde dopingcontroleteams wanneer zij dopingcontroleactiviteiten uitvoeren;
    
    
      c.
      samenwerking ter bespoediging van de tijdige verzending of grenspassage van monsters op zodanige wijze dat de veiligheid en integriteit daarvan behouden blijven;
    
    
      d.
      ondersteuning van de internationale coördinatie van dopingcontroles door verschillende antidopingorganisaties en samenwerking daartoe met het Mondiaal Antidopingagentschap;
    
    
      e.
      bevorderen van de samenwerking tussen dopingcontrolelaboratoria onder hun rechtsmacht en laboratoria onder de rechtsmacht van andere Staten die Partij zijn. In het bijzonder dienen Staten die Partij zijn met geaccrediteerde dopingcontrolelaboratoria laboratoria onder hun rechtsmacht aan te moedigen samen te werken met andere Staten die Partij zijn opdat deze de ervaring, vaardigheden en technieken kunnen verwerven die nodig zijn om eigen laboratoria op te richten indien zij dit zouden wensen;
    
    
      f.
      bevorderen en ondersteunen van wederzijdse controleregelingen tussen aangewezen antidopingorganisaties, in overeenstemming met de Code;
    
    
      g.
      wederzijdse erkenning van de dopingcontroleprocedures en het resultatenbeheer van elke antidopingorganisatie, met inbegrip van de daaruit voortvloeiende sancties op sportgebied, die in overeenstemming zijn met de Code. 
    
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    17
    Vrijwillig Fonds
  
  
    1
    Hierbij wordt een „Fonds voor de uitbanning van doping in de sport’’, hierna te noemen „het Vrijwillig Fonds’’, ingesteld. Het Vrijwillig Fonds bestaat uit funds-in-trust ingesteld in overeenstemming met het Financieel Reglement van UNESCO. Alle bijdragen van Staten die Partij zijn en van andere actoren zijn vrijwillig.
  
  
    2
    De middelen van het Vrijwillig Fonds bestaan uit:
    
      
        a.
        bijdragen van Staten die Partij zijn;
      
      
        b.
        bijdragen, giften of legaten die afkomstig kunnen zijn van:
        
          
            i.
            andere staten;
          
          
            ii.
            organisaties en programma’s van het systeem van de Verenigde Naties, met name het Ontwikkelingsprogramma van de Verenigde Naties, alsmede andere internationale organisaties;
          
          
            iii.
            publieke of private instanties of individuen;
          
        
      
      
        c.
        enige verschuldigde rente op de middelen van het Vrijwillig Fonds;
      
      
        d.
        ingezamelde fondsen en opbrengsten van evenementen die ten behoeve van het Vrijwillig Fonds zijn georganiseerd;
      
      
        e.
        alle andere middelen die zijn toegestaan ingevolge het reglement van het Vrijwillig Fonds, dat door de Conferentie van Partijen zal worden opgesteld.
      
    
  
  
    3
    Bijdragen van de Staten die Partij zijn aan het Vrijwillig Fonds zijn geen vervanging voor de verplichting van de Staten die Partij zijn hun deel van de jaarbegroting van het Mondiaal Antidopingagentschap te betalen.
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Artikel
    18
    Inzet en bestuur van het Vrijwillig Fonds
  
  Middelen van het Vrijwillig Fonds worden door de Conferentie van Partijen toegewezen ten behoeve van de financiering van door hen goedgekeurde activiteiten, in het bijzonder het ondersteunen van Staten die Partij zijn bij het ontwikkelen en implementeren van antidopingprogramma’s, in overeenstemming met de bepalingen van dit Verdrag, daarbij rekening houdend met de doelstelling van het Mondiaal Antidopingagentschap, en kunnen worden ingezet om de operationele kosten van dit Verdrag te dekken. Aan bijdragen aan het Vrijwillig Fonds mogen geen politieke, economische of andere voorwaarden verbonden worden.
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    DEEL
     IV
    VOORLICHTING EN TRAINING
  
  
    Artikel
    19
    Algemene beginselen inzake voorlichting en training
  
  
    1
    De Staten die Partij zijn, verplichten zich, binnen hun mogelijkheden, voorlichtings- en trainingprogramma’s op het gebied van dopingbestrijding te ondersteunen, ontwikkelen of implementeren. Voor de sportgemeenschap in het algemeen dienen deze programma’s gericht te zijn op het bieden van actuele en accurate informatie over:
    
      
        a.
        het gevaar van doping voor de ethische waarden van de sport;
      
      
        b.
        de gevolgen van doping voor de gezondheid.
      
    
  
  
    2
    Voor sporters en begeleiders van sporters, met name tijdens hun basistraining, dienen voorlichtings- en trainingsprogramma’s, in aanvulling op het bovenstaande, gericht te zijn op het bieden van actuele en accurate informatie over:
    
      
        a.
        dopingcontroleprocedures;
      
      
        b.
        de rechten en verantwoordelijkheden van sporters ten aanzien van dopingbestrijding, met inbegrip van informatie over de Code en het antidopingbeleid van de relevante sport- en antidopingorganisaties. Dergelijke informatie dient de gevolgen van het schenden van de dopingregelgeving te omvatten;
      
      
        c.
        de lijst van verboden stoffen en methoden en dispensatie voor therapeutisch gebruik;
      
      
        d.
        voedingssupplementen.
      
    
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    20
    Professionele gedragscodes
  
  De Staten die Partij zijn, moedigen relevante bevoegde sportbonden en -instellingen aan passende gedragscodes, goede praktijken en ethische normen inzake de bestrijding van doping in de sport die in overeenstemming zijn met de Code te ontwikkelen en te implementeren.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    21
    Betrokkenheid van sporters en begeleiders van sporters
  
  De Staten die Partij zijn, bevorderen en ondersteunen, binnen hun mogelijkheden, de actieve betrokkenheid van sporters en begeleiders van sporters bij alle facetten van dopingbestrijding door sportorganisaties en andere relevante organisaties en moedigen sportorganisaties onder hun rechtsmacht aan hetzelfde te doen. 
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    22
    Sportorganisaties en permanente voorlichting en training op het gebied van dopingbestrijding
  
  De Staten die Partij zijn, moedigen sportorganisaties en antidopingorganisaties aan permanente voorlichtings- en trainingsprogramma’s te implementeren voor alle sporters en begeleiders van sporters inzake de in artikel 19 genoemde gebieden.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    23
    Samenwerking bij voorlichting en training
  
  De Staten die Partij zijn, werken met elkaar en met de relevante organisaties samen om, wanneer van toepassing, informatie, expertise en ervaringen met betrekking tot doeltreffende programma’s om doping te bestrijden uit te wisselen.
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    DEEL
     V
    ONDERZOEK
  
  
    Artikel
    24
    Bevorderen van onderzoek naar dopingbestrijding
  
  De Staten die Partij zijn, verplichten zich, binnen hun mogelijkheden, onderzoek naar dopingbestrijding in samenwerking met sportorganisaties en andere organisaties aan te moedigen en te bevorderen met betrekking tot:
  
    
      a.
      manieren en methoden om wetenschappelijk verantwoorde fysiologische en psychologische trainingsprogramma’s op te stellen die de integriteit van de betrokken persoon eerbiedigen;
    
    
      b.
      manieren en methoden om wetenschappelijk verantwoorde fysiologische en psychologische trainingsprogramma’s op te stellen die de integriteit van de betrokken persoon eerbiedigen;
    
    
      c.
      het gebruik van alle nieuwe stoffen en methoden die uit wetenschappelijke ontwikkelingen resulteren.
    
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    25
    De aard van onderzoek ten behoeve van dopingbestrijding
  
  Bij het bevorderen van onderzoek ten behoeve van dopingbestrijding, als vervat in artikel 24, waarborgen de Staten die Partij zijn dat dergelijk onderzoek:
  
    
      a.
      voldoet aan internationaal erkende ethische praktijken; 
    
    
      b.
      niet de toediening aan sporters van verboden stoffen en methoden inhoudt;
    
    
      c.
      uitsluitend wordt uitgevoerd na instelling van adequate voorzorgsmaatregelen teneinde te voorkomen dat de resultaten van onderzoek ten behoeve van dopingbestrijding worden misbruikt en voor dopingdoeleinden worden toegepast.
    
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Artikel
    26
    Delen van de resultaten van onderzoek ten behoeve van dopingbestrijding
  
  Met inachtneming van het toepasselijke nationaal en internationaal recht, delen de Staten die Partij zijn, wanneer van toepassing, de resultaten van beschikbaar onderzoek ten behoeve van dopingbestrijding met de andere Staten die Partij zijn en met het Mondiaal Antidopingsagentschap.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    27
    Sportwetenschappelijk onderzoek
  
  De Staten die Partij zijn, moedigen:
  
    
      a.
      de wetenschappelijke en medische wereld aan sportwetenschappelijk onderzoek uit te voeren in overeenstemming met de beginselen van de Code;
    
    
      b.
      sportorganisaties en begeleiders van sporters onder hun rechtsmacht aan sportwetenschappelijk onderzoek te implementeren dat verenigbaar is met de beginselen van de Code.
    
  
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    DEEL
    VI
    TOEZICHT OP HET VERDRAG
  
  
    Artikel
    28
    Conferentie van Partijen
  
  
    1
    Hierbij wordt een Conferentie van Partijen ingesteld. De Conferentie van Partijen is het hoogste orgaan van dit Verdrag.
  
  
    2
    De Conferentie van Partijen komt in beginsel eenmaal per twee jaar in gewone zitting bijeen. Zij kan in buitengewone zitting bijeenkomen indien zij daartoe beslist of op verzoek van ten minste een derde van de Staten die Partij zijn.
  
  
    3
    Elke Staat die Partij is, heeft een stem bij de Conferentie van Partijen, 
  
  
    4
    De Conferentie stelt haar eigen reglement van orde vast.
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Artikel
    29
    Adviesorgaan van en waarnemers bij de Conferentie van Partijen
  
  Het Mondiaal Antidopingagentschap wordt uitgenodigd als adviesorgaan van de Conferentie van Partijen. Het Internationaal Olympisch Comité, het Internationaal Paralympisch Comité, de Raad van Europa en het Intergovernmental Committee for Physical Education and Sport (CIGEPS) worden als waarnemers uitgenodigd. De Conferentie van Partijen kan besluiten andere relevante organisaties als waarnemers uit te nodigen.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    30
    Taken van de Conferentie van Partijen
  
  
    1
    Naast de taken vervat in de andere bepalingen van dit Verdrag, heeft de Conferentie van Partijen de volgende taken:
    
      
        a.
        bevorderen van de doelstelling van dit Verdrag;
      
      
        b.
        bespreken van de relatie met het Modiaal Antidopingagentschap en bestuderen van de mechanismen van de financiering van de jaarlijkse basisbegroting van het Agentschap. Staten die geen Partij zijn, kunnen worden uitgenodigd aan de bespreking deel te nemen;
      
      
        c.
        aannemen van een plan voor de toepassing van de middelen van het Vrijwillig Fonds, in overeenstemming met artikel 18;
      
      
        d.
        onderzoeken van de door de Staten die Partij zijn in overeenstemming met artikel 31 ingediende verslagen;
      
      
        e.
        toetsen, op permanente basis, van het toezicht op de naleving van dit Verdrag in antwoord op de ontwikkeling van systemen voor dopingbestrijding, in overeenstemming met artikel 31. Elk toezichtsmechanisme dat of elke toezichtsmaatregel die buiten het kader van artikel 31 valt, wordt gefinancierd door het ingevolge artikel 17 ingestelde Vrijwillig Fonds;
      
      
        f.
        onderzoeken van ontwerpwijzigingen van dit Verdrag in verband met de aanname daarvan;
      
      
        g.
        onderzoeken ter goedkeuring, in overeenstemming met artikel 34 van het Verdrag, van wijzigingen van de Lijst van verboden middelen en methoden en van de Normen voor het verlenen van dispensatie voor therapeutisch gebruik aangenomen door het Mondiaal Antidopingagentschap;
      
      
        h.
        omschrijven en implementeren van de samenwerking tussen de Staten die Partij zijn en het Mondiaal Antidopingagentschap in het kader van dit Verdrag;
      
      
        i.
        ten behoeve van elk van haar zittingen verzoeken om een verslag van het Mondiaal Antidopingagentschap inzake de implementatie van de Code ter toetsing. 
      
    
  
  
    2
    De Conferentie van Partijen kan bij de uitoefening van haar taken samenwerken met andere intergouvernementele instanties.
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    31
    Nationale verslagen aan de Conferentie van Partijen
  
  De Staten die Partij zijn, zenden de Conferentie van Partijen elke twee jaar via het Secretariaat, in een van de officiële talen van UNESCO, alle relevante informatie toe betreffende door hen getroffen maatregelen te behoeve van de naleving van de bepalingen van dit Verdrag.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    32
    Secretariaat van de Conferentie van Partijen
  
  
    1
    Het Secretariaat van de Conferentie van Partijen wordt verzorgd door de Directeur-Generaal van UNESCO.
  
  
    2
    Op verzoek van de Conferentie van Partijen maakt de Directeur-Generaal van UNESCO in zo ruim mogelijke mate gebruik van de diensten van het Mondiaal Antidopingagentschap op de door de Conferentie van Partijen overeengekomen voorwaarden.
  
  
    3
    Kosten die verband houden met het functioneren van het Verdrag worden gefinancierd uit de reguliere begroting van UNESCO uit bestaande middelen op een passend niveau, uit het ingevolge artikel 17 ingestelde Vrijwillig Fonds of uit een passende combinatie daarvan, zoals elke twee jaar wordt vastgesteld. Financiering van het Secretariaat uit de reguliere begroting dient zo beperkt mogelijk te blijven, ervan uitgaande dat het Verdrag ook door vrijwillige financiering ondersteund dient te worden.
  
  
    4
    Het Secretariaat stelt de documentatie van de Conferentie van Partijen op, alsmede de ontwerpagenda van haar bijeenkomsten, en waarborgt de implementatie van de beslissingen ervan.
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    33
    Wijzigingen
  
  
    1
    Elke Staat die Partij is, kan door middel van een schriftelijke mededeling gericht aan de Directeur-Generaal van UNESCO voorstellen doen tot wijziging van dit Verdrag. De Directeur-Generaal verzendt deze mededeling aan alle Staten die Partij zijn. Indien, binnen zes maanden na de datum van verzending van de mededeling, ten minste de helft van de Staten die Partij zijn ermee instemmen, legt de Directeur-Generaal dergelijke voorstellen voor aan de volgende zitting van de Conferentie van Partijen. 
  
  
    2
    Wijzigingen worden aangenomen door de Conferentie van Partijen met een tweederde meerderheid van de Staten die Partij zijn die aanwezig zijn en hun stem uitbrengen.
  
  
    3
    Zodra wijzigingen van dit Verdrag zijn aangenomen worden zij ter bekrachtiging, aanvaarding, goedkeuring of toetreding voorgelegd aan de Staten die Partij zijn.
  
  
    4
    Ten aanzien van de Staten die Partij zijn die deze wijzigingen hebben bekrachtigd, aanvaard, goedgekeurd of die ertoe zijn toegetreden, treedt dit Verdrag in werking drie maanden na de nederlegging van de in het derde lid van dit artikel bedoelde akten door twee derde van de Staten die Partij zijn. Vervolgens treedt de genoemde wijziging voor elke Staat die deze bekrachtigt, aanvaardt, goedkeurt of ertoe toetreedt in werking drie maanden na de datum van nederlegging door die Staat die Partij is van zijn akte van bekrachtiging, aanvaarding, goedkeuring of toetreding.
  
  
    5
    Een Staat die Partij wordt bij dit Verdrag na de inwerkingtreding van wijzigingen overeenkomstig het vierde lid van dit artikel wordt geacht:
    
      
        a.
        Partij te zijn bij het aldus gewijzigde Verdrag;
      
      
        b.
        Partij te zijn bij het ongewijzigde Verdrag ten aanzien van elke Staat die Partij is die niet gebonden is door de wijzigingen; tenzij hij blijk geeft van een andere bedoeling.
      
    
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Artikel
    34
    Specifieke wijzigingsprocedure voor de Bijlagen bij het Verdrag
  
  
    1
    Indien het Mondiaal Antidopingagentschap de Lijst van verboden middelen en methoden of de Normen voor het verlenen van dispensatie voor therapeutisch gebruik wijzigt, kan hij, door middel van een schriftelijke kennisgeving gericht aan de Directeur-Generaal van UNESCO, hem of haar in kennis stellen van deze wijzigingen. De Directeur-Generaal brengt deze veranderingen als voorgestelde wijzigingen van de desbetreffende Bijlagen bij dit Verdrag onverwijld ter kennis van alle Staten die Partij zijn. Wijzigingen van de Bijlagen worden door de Conferentie van Partijen goedgekeurd, hetzij tijdens een van haar zittingen, hetzij door middel van schrifteljk overleg.
  
  
    2
    De Staten die Partij zijn, kunnen binnen 45 dagen na de kennisgeving van de Directeur-Generaal hun bezwaar tegen de voorgestelde wijziging kenbaar maken, hetzij schriftelijk in het geval van schriftelijk overleg aan de Directeur-Generaal, hetzij tijdens een zitting van de Conferentie van Partijen. Tenzij twee derde van de Staten die Partij zijn bezwaar aantekenen, wordt de voorgestelde wijziging geacht te zijn goedgekeurd door de Conferentie van Partijen.
  
  
    3
    Door de Conferentie van Partijen goedgekeurde wijzigingen worden door de Directeur-Generaal ter kennis van de Staten die Partij zijn gebracht. Zij treden 45 dagen na deze kennisgeving in werking, uitgezonderd ten aanzien van elke Staat die Partij is die de Directeur-Generaal vooraf ervan in kennis heeft gesteld dat hij deze wijzigingen niet aanvaardt.
  
  
    4
    Een Staat die Partij is die de Directeur-Generaal ervan in kennis heeft gesteld dat hij een wijziging die overeenkomstig de voorgaande leden is goedgekeurd niet aanvaardt, blijft gebonden door de ongewijzigde Bijlagen.
  
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    DEEL
     VII
    SLOTBEPALINGEN
  
  
    Artikel
    35
    Federale of niet-unitaire constitutionele stelsels
  
  De volgende bepalingen zijn van toepassing op Staten die Partij zijn met een federaal of niet-unitair constitutioneel systeem:
  
    
      a.
      Ten aanzien van de bepalingen van dit Verdrag, waarvan de implementatie onder de rechtsmacht van de federale of centrale wetgevende macht valt, zijn de verplichtingen van de federale of centrale regering dezelfde als die voor Staten die Partij zijn die geen federale staten zijn;
    
    
      b.
      Ten aanzien van de bepalingen van dit Verdrag, waarvan de implementatie onder de rechtsmacht valt van de afzonderlijke Staten, landen, provincies of kantons die door het constitutionele stelsel van de federatie niet verplicht zijn wetgevende maatregelen te treffen, stelt de federale regering de bevoegde autoriteiten van dergelijke Staten, landen, provincies of kantons in kennis van genoemde bepalingen, tezamen met haar aanbeveling deze aan te nemen.
    
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    36
    Bekrachtiging, aanvaarding, goedkeuring of toetreding
  
  Dit Verdrag dient te worden bekrachtigd, aanvaard, goedgekeurd of hiertoe dient te worden toegetreden door de lidstaten van UNESCO in overeenstemming met hun onderscheiden grondwettelijke procedures. De akten van bekrachtiging, aanvaarding, goedkeuring of toetreding dienen te worden nedergelegd bij de Directeur-Generaal van UNESCO.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    37
    Inwerkingtreding
  
  
    1
    Dit Verdrag treedt in werking op de eerste dag van de maand die volgt op het verstrijken van een maand na de datum van nederlegging van de dertigste akte van bekrachtiging, aanvaarding, goedkeuring of toetreding. 
  
  
    2
    Ten aanzien van elke Staat die later zijn instemming door het Verdrag te worden gebonden tot uitdrukking brengt, treedt het Verdrag in werking op de eerste dag van de maand die volgt op het verstrijken van een tijdvak van een maand na de datum van nederlegging van zijn akte van bekrachtiging, aanvaarding, goedkeuring of toetreding.
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007
  
    Artikel
    38
    Uitbreiding tot andere gebieden van het Verdrag
  
  
    1
    Elke Staat kan bij de nederlegging van zijn akte van bekrachtiging, aanvaarding, goedkeuring of toetreding het grondgebied of de grondgebieden aanduiden voor de internationale betrekkingen waarvan hij verantwoordelijk is en waarop dit Verdrag van toepassing is.
  
  
    2
    Elke Staat die Partij is, kan op een later tijdstip door middel van een verklaring gericht aan UNESCO, de toepassing van dit Verdrag uitbreiden tot elk ander grondgebied dat in de verklaring wordt genoemd. Ten aanzien van een dergelijk grondgebied treedt het Verdrag in werking op de eerste dag van de maand die volgt op het verstrijken van een tijdvak van een maand na de datum van ontvangst van die verklaring door de Depositaris.
  
  
    3
    Elke verklaring die wordt gedaan uit hoofde van de twee voorgaande leden kan, met betrekking tot elk grondgebied dat in de verklaring wordt genoemd, worden ingetrokken door middel van een aan UNESCO gerichte kennisgeving. De intrekking wordt van kracht op de eerste dag van de maand die volgt op het verstrijken van een tijdvak van een maand na de datum van ontvangst van een dergelijke kennisgeving door de Depositaris.
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    39
    Opzegging
  
  Elke Staat die Partij is, kan dit Verdrag opzeggen. De opzegging wordt door middel van een schriftelijke akte ter kennis gebracht en bij de Directeur-Generaal van UNESCO nedergelegd. De opzegging wordt van kracht op de eerste dag van de maand die volgt op het verstrijken van een tijdvak van zes maanden na ontvangst van de akte van opzegging. Dit heeft in geen geval gevolgen voor de financiële verplichtingen van de desbetreffende Staat die Partij is tot de datum waarop de opzegging van kracht wordt.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    40
    Depositaris
  
  De Directeur-Generaal van UNESCO is de Depositaris van dit Verdrag en de wijzigingen daarvan. De Directeur-Generaal van UNESCO stelt als Depositaris alle Staten die Partij zijn bij dit Verdrag alsmede de andere lidstaten van de Organisatie in kennis van:
  
    
      a.
      de nederlegging van elke akte van bekrachtiging, aanvaarding, goedkeuring of toetreding;
    
    
      b.
      de datum van inwerkingtreding van dit Verdrag overeenkomstig artikel 37;
    
    
      c.
      elk verslag opgesteld uit hoofde van de bepalingen van artikel 31;
    
    
      d.
      elke wijziging van het Verdrag of van de Bijlagen aangenomen in overeenstemming met de bovenstaande artikelen 33 en 34 en de datum waarop de wijziging van kracht wordt;
    
    
      e.
      elke uit hoofde van de bepalingen van artikel 38 gedane verklaring of kennisgeving;
    
    
      f.
      elke uit hoofde van de bepalingen van artikel 39 gedane kennisgeving en de datum waarop de opzegging van kracht wordt;
    
    
      g.
      elke andere akte, kennisgeving of mededeling met betrekking tot dit Verdrag.
    
  
200619415-09-200617-11-20068815-06-20152007518-01-200701-02-2007Abusievelijk geeft het Tractatenblad een opdracht tot een
    correctie van onderdeel d die niet kan worden doorgevoerd.
  
    Artikel
    41
    Registratie
  
  In overeenstemming met artikel 102 van het Handvest van de Verenigde Naties wordt dit Verdrag geregistreerd bij het Secretariaat van de Verenigde Naties op verzoek van de Directeur-Generaal van UNESCO.
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    42
    Gezaghebbende teksten
  
  
    1
    Dit Verdrag met inbegrip van de Bijlagen daarbij is opgesteld in de Arabische, de Chinese, de Engelse, de Franse, de Russische en de Spaanse taal, zijnde alle teksten gelijkelijk gezaghebbend.
  
  
    2
    De Aanhangsels bij dit Verdrag zijn opgesteld in de Arabische, de Chinese, de Engelse, de Franse, de Russische en de Spaanse taal.
  
200619415-09-200617-11-20062007518-01-200701-02-2007
  
    Artikel
    43
    Voorbehouden
  
  Voorbehouden die onverenigbaar zijn met het onderwerp en het doel van dit Verdrag zijn niet toegestaan.
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
    GEDAAN te Parijs, op 19 oktober 2005, in twee oorspronkelijke exemplaren voorzien van de handtekening van de Voorzitter van de Algemene Conferentie van UNESCO tijdens haar 33e zitting en van de Directeur-Generaal van UNESCO, die zullen worden nedergelegd in het archief van UNESCO.
  
200619415-09-200617-11-20062007518-01-200701-02-2007200619415-09-200617-11-20062007518-01-200701-02-2007
  
  
    Bijlage 
    I
    De Lijst van verboden stoffen en methoden - Internationale norm
  
  
  
    De tekst van de vertaling is niet beschikbaar.
  
20158711-06-201520158815-06-201501-01-2015
20158711-06-201520158815-06-201501-01-2015
  
  
    Bijlage
    II
    NORM VOOR HET VERLENEN VAN DISPENSATIE VOOR THERAPEUTISCH GEBRUIK
  
  
  
    De tekst van de vertaling is niet beschikbaar.
  
20092627-02-200920092627-02-200901-01-2009
200619415-09-200617-11-20062007518-01-200701-02-2007

200619415-09-200617-11-20062007518-01-200701-02-2007